5,335 results on '"CIBERCV"'
Search Results
2. LEft VEntricuLar Activation Time Shortening With Physiological Pacing vs Biventricular Resynchronization Therapy (LEVEL-AT)
- Author
-
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), and Josep Lluis Mont Girbau, Head of Arrhythmia Section. Professor of Cardiology
- Published
- 2022
3. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
- Author
-
Catapano, Alberico L, Tokgözoğlu, Lale, Banach, Maciej, Gazzotti, Marta, Olmastroni, Elena, Casula, Manuela, Ray, Kausik K, the Lipid Clinics Network, Alaa ABDELRAZIK (University Hospital of North Midland, United Kingdom), Alberto MELLO E SILVA (Sociedade Portuguesa de Aterosclerose, Portugal), Alexander VONBANK (VIVIT Institute, Austria), Alexandros, D TSELEPIS (Dept of Chemistry, Atherothrombosis Research Center, University of Ioannina, Greece), Alper SONMEZ (Department of Endocrinology and Metabolism, Ankara Guven Hospital, Turkey), Angelina PASSARO (Department of Translational Medicine, University of Ferrara &, Center for the Study and Treatment of Metabolic Diseases, Atherosclerosis, and Clinical Nutrition, University Hospital of Ferrara Arcispedale Sant’Anna, Italy), Anja VOGT (Medizinische Klinik und Poliklinik IV, Klinikum der Universit¨at München, Germany), Ann MERTENS (Clinical and Experimental Endocrinology, Leuven, Ku, Leuven, Belgium), Ann VERHAEGEN (Antwerp University Hospital, Belgium), Arman, S POSTADZHIYAN (Medical University of Sofia, Saint Anna University Hospital, Departement of Cardiology, Bulgaria), BAHADIR KIRILMAZ (Canakkale Onsekiz Mart University, Medical Faculty Cardiology Dept, Baris GUNGOR (University of Health Sciences Dr. Siyami Ersek Hospital, Turkey), Berit S HEDEGAARD (Aalborg University, Denmark), Bertrand CARIOU (Nantes Universit´e, Chu, Nantes, Cnrs, Inserm, l’institut du thorax, Nantes, France), Britta OTTE (Universit¨atsklinikum Münster, Lipidambulanz, Germany), Bu˘gra ¨OZKAN (Mersin University, Turkey), of cardiology, Christ BERGE (Dept., Unversity Hopsital, Haukeland., Norway), F EBENBICHLER (Department for Internal Medicine I, Christoph, Medical University Innsbruck, Austria), Christoph J BINDER (Medical University of Vienna, Austria), Christoph OLIVIER (Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg, Conrad AZZOPARDI (Mater Dei Hospital, Malta), Cristina SOLER (Lipid Unit, Hospital de Sta Caterina, Spain), Dan GAITA (Universitatea de Medicina si Farmacie Victor Babes din Timisoara &, Clinica de Cardiologie, Institutul de Boli Cardiovasculare Timisoara, Romania), Daniel WEGHUBER (Department of Pediatrics, Paracelsus Medical University, Dilek URAL (Koç University School of Medicine Department of Cardiology, Turkey), Diogo CRUZ (Hospital de Cascais - Dr. Jos´e de Almeida, Portugal), Dragos VINEREANU (University of Medicine and Pharmacy, University and Emergency Hospital, Bucharest, Romania), Elena D PENCU (Grand Hˆopital de Charleroi GHDC, Belgium), Emil HAGSTR¨OM (Dept of medical sciences, Uppsala, University, Sweden), Erik B SCHMIDT (Aalborg University, Denmark), Erik, S STROES (Dept of vascular medicine, Amsterdamumc, The, Netherlands), Evangelos LIBEROPOULOS (1st Department of Propedeutic Medicine, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens Laiko, Fabian DEMEURE (CHU UCL Namur - Site Godinne, Belgium), Fabio FIMIANI (Azienda Ospedaliera di Rilievo Nazionale AORN Dei Colli, Monaldi', 'V., Unit of Inherited and Rare Cardiovascular Diseases, Italy, ), Fabio PELLEGATTA (Center for the Study of Atherosclerosis. Bassini Hospital. Cinisello Balsamo, Italy), Fahri BAYRAM (Erciyes University, Turkey), Finn L HENRIKSEN (Department of Cardiology Odense University Hospital, Denmark), Florian H¨OLLERL (1st Medical Department, Landstrasse, Clinic, Vienna Health Association, Francesco CIPOLLONE (Clinica Medica Institute of, Department of Medicine and Aging Sciences, d’Annunzio' University, 'G., Francisco ARAÚJO (Hospital Lusíadas, Portugal), Franck BOCCARA (Sorbonne Universit´e, Groupe de Recherche Clinique number 22, C2MV—Complications Cardiovasculaires et M´etaboliques chez les Patients Vivant avec le Virus de l’Immunod´eficience Humaine, Institut National de la Sant´e et de la Recherche M´edicale Unit´e Mixte de Recherche, S 938, Centre de Recherche Saint-Antoine, Institut Hospital Universitaire de Cardiom ´etabolisme et Nutrition Cardiologie, Hˆopital Saint Antoine Assistance Publique–Hˆopitaux de Paris, Paris, France), François PAILLARD (Cardiologie et Centre Clinico-Biologique des Lipides et Ath´eroscl´erose, Chu, Rennes, France), Imre University Teaching Hospital, Gabor SIMONYI (DBC St., Metabolic, Center, Lipid, Center, Hungary), Gabriella IANNUZZO (Department of Clinical Medicine and Surgery. University of Naples Federico II, Italy), Giuseppe MANDRAFFINO (Department of Clinical and Experimental Medicine, - Lipid Center, University of Messina, Graham BAYLY (Dept Clinical Biochemistry, University Hospitals Bristol, United, Kingdom), Gustavs LATKOVSKIS (Institute of Cardiology and Regenerative Medicine, University of Latvia &, Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital &, University of Latvia, Latvia), Gy¨orgy PARAGH (Division of Metabolic Disorders, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary), Hana ROSOLOVA (Charles University Prague Medical Hospital in Pilsen, Czech Republic), Handrean SORAN (Central Manchester University Hospital NHS Foundation Trust, United Kingdom), Helle KANSTRUP (Department of cardiology, Aarhus University hospital, Denmark), Hermann TOPLAK (Department of Medicine, Division of Endocrinology and Diabetology, Medical University Graz, Hülya ÇIÇEKÇIO ˘GLU (ankara bilkent city hospital, Turkey), Inanc ARTAC (Department of Cardiology, Kafkas University Hospital, Ioanna GOUNI-BERTHOLD (Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Irfan, V DUZEN (Gaziantep University, Cardiology, Department, Isabel M PALMA (CHUPORTO - Centro Hospitalar Universit ´ario do Porto, Portugal), Istvan REIBER (Szent Gyorgy University Teaching Hospital of Fejer County, Hungary), Iveta DZIVITE-KRISANE (Children’s University Hospital, Latvia), Jeanine, E ROETERS VAN LENNEP (Department of Internal medicine, Erasmus MC University Medical Center, Jean-Luc, J BALLIGAND (Institut de Recherche Exp´erimentale et Clinique, Universite catholique de Louvain, Bruxelles), Joao C PORTO (CHUC, Portugal), Jo˜ao, S DUARTE (Hospital Egas Moniz, Lisboa, Portugal), Johan DE SUTTER (AZ Maria Middelares Hospital Gent, Belgium), Jos´e L´OPEZ-MIRANDA (Lipid and Arteriosclerosis Unit. Department of Internal Medicine. Hospital Universitario Reina Sofia. IMIBIC. University of Cordoba. CiberOBN, Spain), Jose M MOSTAZA (Hospital La Paz-Carlos III, Spain), Jurgita PLISIENE (Lithuanian University of Health sciences, Lithuania), Kadir, U MERT (Eskis ¸ehir Osmangazi University, Department of Cardiology, Kirsten, B HOLVEN (Department of Nutrition, University of Oslo and National Advisory unit on FH, Oslo University Hospital, Kjetil RETTERSTØL (The Lipid Clinic, Oslo University Hospital and Department of Nutrition, University of Oslo, Kristian, K THOMSEN (University Hospital of South Denmark, Esbjerg, Denmark), Lale TOKGOZOGLU (Hacettepe University, Turkey), Laszlo BAJNOK (1st Department of Medicine, Medical, School, University of Pecs, Lia E BANG (Copenhagen University Hospital, Denmark), Liliana GRIGORE (IRCCS Multimedica, Italy), Lluís MASANA (Hospital Universitari Sant Joan. Universitat Rovira i Virgili. CIBERDEM. Reus, Spain), Loukianos S RALLIDIS (University General Hospital Attikon, Greece), Maciej BANACH (Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland), Małgorzata WALU´S-MIARKA (Jagiellonian University Medical College, Of Metabolic Diseases and Diabetology, Dept., Manuel CASTRO CABEZAS (Franciscus Gasthuis &, Vlietland Rotterdam, The Netherlands), Marcello ARCA (Sapienza University of Rome, Italy), Margus VIIGIMAA (North Estonia Medical Centre, Tallinn University of Technology, Estonia), Martin, P BOGSRUD (Unit for Cardiac and Cardiovascular Genetics, Matej MLINARIˇC (Department of Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, Slovenia), Matteo PIRRO (Section of Internal Medicine, Angiology and Arteriosclerosis Diseases, Maurizio AVERNA (Department PROMISE-University of Palermo &, Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy), Meral KAYIKCIOGLU (Ege University Medical School Department of Cardiology, Turkey), Merete HEITMANN (Bispebjerg-Frederiksberg University Hospital, Denmark), Mette MOURIDSEN (Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Michal VRABLIK (3rd Department of Internal Medicine, General University Hospital and 1st Medical Faculty, Charles, University, Prague, Czech, Republic), Michel FARNIER (PEC2, University of Bourgogne Franche-Comt´e, Laboratory Medicine, Michel R LANGLOIS (Dept., Jan Hospital, AZ St., Belgium), Milad KHEDR (Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Muge ILDIZLI DEMIRBAS (Kartal Kosuyolu Research and Training Hospital, Turkey), Myra TILNEY (Lipid Clinic, Mater Dei Hospital &, Dept of Medicine, University of Malta Medical School, Malta), Nadia CITRONI (Internal Medicine, APSS Trento Hospital, Of Internal Medicine, Niels P RIKSEN (Dept., Radboud university medical center, Nikolay M RUNEV (UMHAT Alexandrovska, Bulgaria), Nora KUPSTYTEKRISTAPONE (Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Lithuania), Olena MITCHENKO (NSC, Clinical and Regenerative Medicine of the NAMS of Ukraine, Ukraine), Oliver WEING¨ARTNER (Universit¨atsklinikum Jena, Department of Internal Medicine, I, Oner OZDOGAN (University of Health Sciences, Izmir Faculty of Medicine, Tepecik Training and Research Hospital, Ovidio MU˜NIZGRIJALVO (Hospital Virgen del Rocío, Spain), Ozcan BASARAN (Mugla Sitki Kocman University, Pankaj GUPTA (University Hospitals of Leicester, United Kingdom), Paolo PARINI (Cardio Metabolic Unit, Karolinska, Institutet, and Theme Inflammation and Ageing, Karolinska University Hospital Huddinge, Patrizia SUPPRESSA (Department of Internal Medicine and rare disease Centre, Bari, Italy), Paul DOWNIE (Salisbury NHS Foundation trust, United Kingdom), Pavel JESINA (Metabolic Center General University Hospital, Czech Republic), of Internal Medicine, Pavel KRAML (Dept., Third Faculty of Medicine, Charles University and Kr´alovsk´e Vinohrady University Hospital Prague, Pawel BURCHARDT (Department of Cardiology, Cardiovascular, Unit, Hospital, J. Stru´s., Pozna´n, &, Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Pozna´n, Poland), Pedro VALDIVIELSO (Hospital VIRGEN DE LA VICTORIA, Spain), Pedro VON HAFE (Instituto Cuf, Portugal), Dept, Peter FASCHING (5th Med., Clinic, Ottakring, Philippe MOULIN (Hospices civils de Lyon/INSERM/Universit ´e Lyon1, Hˆopital Louis Pradel, F´ed´eration, D’Endocrinologie, Quit´eria RATO (Sociedade Portuguesa de Aterosclerose, Portugal), Reinhold INNERHOFER (Medical University Vienna, Austria), Renata C´IFKOV´A (Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer University Hospital, Rene VALERO (Aix Marseille Univ, Aphm, Inserm, Inrae, C2vn, University Hospital La Conception, Department of Nutrition, Metabolic Diseases and Endocrinology, Scicali, Roberto, Robin URB´ANEK (Internal medicine, Obezita-Ormiga, s. r. o., Roma KAVALIAUSKIENE (Klaip˙ eda Seamen’s Hospital, Lituania), Roman CIBULKA (Department of paramedic science, medical diagnostics studies and public health, Faculty of Health Care Studies, University of West Bohemia, Sabina ZAMBON (Department of Medicine, - DIMED, University of Padova, Sergio D’ADDATO (University of Bologna. IRCCS S. Orsola Bologna, Italy), Stanislav ZEMEK (Lipidova ambulance, Czech Republic), Stefano ROMEO (Gothenburg University, Sweden), Stephanie K¨ONEMANN (Department of Internal Medicine, B, University Medicine Greifswald, DZHK (German Centre for Cardiovascular Research), Susanne GREBER-PLATZER (Clinical Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Thomas STULNIG (Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University Vienna &, Third Medical Department and Karl Landsteiner Institute for Metabolic Diseases and Nephrology, Clinic, Hietzing, Vienna, Austria), Thomas MUHR (Dept of Cardiology, Link¨oping University Hospital, Tina, Z KHAN (Consultant Cardiologist, Royal Brompton and Harefield Hospitals Part of Guy’s and St Thomas’ NHS Foundation Trust, Tomas FREIBERGER (Centre of Cardiovascular Surgery and Transplantation, Brno &, Medical, Faculty, Masaryk, University, Brno, Tom´aˇs ˇS´ALEK (Metabolic Clinic, Tomas Bata Hospital, Zlín, Tomas VASYLIUS (Republican Panevezys hospital, Of Cardiology, Dep., Lithuania), Ulrich LAUFS (Klinik und Poliklinik für Kardiologie, Universit ¨atsklinikum Leipzig, Ulrike SCHATZ (University Hospital Carl Gustav Carus Dresden at the Technical University Dresden, Department of Internal Medicine III, Urh GROSELJ (UMC, - University Children’s Hospital Ljubljana, University of Ljubljana, Victoria MARCO-BENEDI (Hospital Universitario Miguel Servet, Iisa, Cibercv, Vincent MAHER (Advanced Lipid Management and Research ALMAR centre, Tallaght University Hospital, Ireland), Vladimír BLAHA (University Hospital Hradec Kr´alov´e and Charles University, Faculty of Medicine in Hradec Kr´alov´e, 3rd Department of Internal Medicine, - Metabolism and Gerontology, Vladimir SOSKA (Department of Clinical Biochemistry, St. Anne’s University Hospital Brno, 2nd Clinic of Internal Medicine, Masaryk University Brno, Volker JJ SCHETTLER (Centre of Nephrology G¨ottingen, Germany), Wolfgang REINHARDT (SUS Malmoe, Sweden), Xavier PINT´O (Hospital Universitari de Bellvitge-Idibell-UB-CiberObn, Spain), Yoto YOTOV (Second Cardiology Clinic, Marina, University Hospital Sv., Medical University of Varna, Zaneta PETRULIONIENE (Vilnius University Medical Faculty, Vilnius University Hospital Santaros klinikos, Lithuania), ˇZeljko REINER (Department for Metabolic Diseases, University Hospital Center Zagreb, and Croatia, ).
- Subjects
Clinicians ,Clinical evaluation ,Cardiology and Cardiovascular Medicine ,Cardiovascular risk ,Lipoprotein(a) - Published
- 2023
4. IgA Nephropathy Is the Most Common Underlying Disease in Patients With Anticoagulant-Related Nephropathy
- Author
-
Universidad de Sevilla. Departamento de Medicina, Comunidad Autónoma de Madrid, Consejería de Salud y Familias. Junta de Andalucía, Instituto de Salud Carlos III, Red de Investigacion Renal (RedInRen), Centro Español de Investigación Biomédica en Enfermedades Cardiovasculares (CIBERCV), Ministerio de Ciencia e Innovación (MICIN). España, Sociedad Española de Nefrología (SEN), Trujillo, H., Sandino, J., Cavero, Teresa, Caravaca-Fontan, F, Gutierrez, E., Sevillano, A.M., Muñoz Terol, José Manuel, Praga, Manuel, Universidad de Sevilla. Departamento de Medicina, Comunidad Autónoma de Madrid, Consejería de Salud y Familias. Junta de Andalucía, Instituto de Salud Carlos III, Red de Investigacion Renal (RedInRen), Centro Español de Investigación Biomédica en Enfermedades Cardiovasculares (CIBERCV), Ministerio de Ciencia e Innovación (MICIN). España, Sociedad Española de Nefrología (SEN), Trujillo, H., Sandino, J., Cavero, Teresa, Caravaca-Fontan, F, Gutierrez, E., Sevillano, A.M., Muñoz Terol, José Manuel, and Praga, Manuel
- Abstract
Introduction Anticoagulant-related nephropathy (ARN) is a relatively novel recognized entity characterized by hematuria-associated acute kidney injury (AKI) in the context of overanticoagulation. Preexisting or underlying kidney disease seems to be a predisposing factor; however, few studies have described histologic findings in patients with ARN. We aimed to evaluate underlying kidney pathology in patients on oral anticoagulation who presented an episode of AKI with hematuria in whom a kidney biopsy was performed. Methods Retrospective observational multicenter case study in patients treated with oral anticoagulants who developed macroscopic or intense hematuria followed by AKI. Only patients with available kidney biopsy specimens were included. Histologic findings and clinical data throughout follow-up were analyzed. Results A total of 26 patients were included with a median age of 75 years (62–80) and a follow-up period of 10.1 months. Of the patients, 80% were male, and most cases (92%) were on anticoagulation with vitamin K antagonists (VKAs). At admission, median serum creatinine (SCr) level was 4.2 mg/dl (2.8–8.2), median international normalized ratio (INR) 2.4 (1.5–3.4), and 11 patients (42%) required acute dialysis during hospitalization. Kidney biopsy results revealed that all patients except 1 had an underlying nephropathy: IgA nephropathy (IgAN) in 19, probable IgAN in 1, diabetic nephropathy in 3, nephrosclerosis in 1, and idiopathic nodular glomerulosclerosis in 1. At 12 weeks after discharge, only 6 subjects (24%) attained complete kidney recovery whereas 7 (28%) remained on chronic dialysis. Conclusion IgAN was the most common underlying kidney disease in our biopsy-proven series of ARN, in which a significant percentage of patients did not achieve kidney function recovery.
- Published
- 2022
5. Immune synapse instructs epigenomic and transcriptomic functional reprogramming in dendritic cells
- Author
-
Ana Alcaraz-Serna, Centro Nacional de Investigaciones Cardiovasculares (Cnic), Madrid, Spain., Enrique Vázquez, Ester Marina-Zárate, Juliana Barreto de Alburquerque, Jens V. Stein, Erika Lorenzo-Vivas, Fátima Sánchez-Cabo, Manuel Gómez, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (Cibercv), Francisco Sánchez-Madrid, Diego Calzada-Fraile, Irene Fernández-Delgado, Ana Dopazo, Nora Ruef, Daniel Torralba, Eugenio Bustos-Morán, and Almudena R. Ramiro
- Subjects
Transcriptome ,Biology ,Reprogramming ,Immunological synapse ,Cell biology ,Epigenomics - Published
- 2021
- Full Text
- View/download PDF
6. Metabolic adaptations in spontaneously immortalized PGC-1α knock-out mouse embryonic fibroblasts increase their oncogenic potential
- Author
-
Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (Cibercv), Sebastián Cerdán, Ignacio Prieto, Mª Begoña Ruiz-Larrea, R. Manuel Portero, Antonio Martínez-Ruiz, José Ignacio Ruiz-Sanz, Raquel García-Gómez, Carmen Rubio-Alarcón, n. Leioa (Spain)., Rebeca Berdún, Reinald Pamplona, María Monsalve, Mariona Jové, and Euskal Herriko Unibertsitea. Barrio Sarriena s
- Subjects
Knockout mouse ,Biology ,Embryonic stem cell ,Cell biology - Published
- 2019
- Full Text
- View/download PDF
7. MKK6: a novel player in cardiac hypertrophy and sudden cardiac death
- Author
-
Ayelén M Santamans, Elisa Manieri, Eric N. Jimenez Vazquez, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (Cibercv), Madrid, Spain., María del Valle Montalvo, Bárbara González-Terán, Rafael Romero-Becerra, José Jalife, Luis Leiva-Vega, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos Iii, Madrid, Spain., María Elena Rodríguez, Guadalupe Sabio, Luis Jesús Jiménez Borreguero, Ivana Nikolic, Laura Sanz, Víctor Buendía, Roberto Ramos Mondragon, Guadalupe Guerrero Serna, Daniela Ponce-Balbuena, and David Filgueiras
- Subjects
medicine.medical_specialty ,business.industry ,Cardiac hypertrophy ,Internal medicine ,medicine ,Cardiology ,medicine.disease ,business ,Sudden cardiac death - Published
- 2019
- Full Text
- View/download PDF
8. P5542A simple CHA2DS2-VASc derived score for assessing long-term prognosis in STEMI patients (cardioCHUS STEMI registry)
- Author
-
F. Gómez Peña, Cibercv, A. Avila Carrillo, J R Gonzalez Juanatey, X. Sanmartin Pena, B Alvarez Alvarez, D Lopez Otero, A. Redondo Dieguez, B Cid Alvarez, and R. Trillo Nouche
- Subjects
medicine.medical_specialty ,business.industry ,Medicine ,Cardiology and Cardiovascular Medicine ,business ,Intensive care medicine ,Simple (philosophy) ,Term (time) - Published
- 2018
- Full Text
- View/download PDF
9. Vascular damage in obesity associated to pge2 derived mpges-1 through aldosterone/mineralocorticoid-receptor route
- Author
-
Dpt. Farmacología, Facultad de Medicina, Uam. IdiPAZ. Madrid, Spain., Constanza Ballesteros, María González Amor, Mercedes Salaices, Ana M. Briones, Ana B. García Redondo, Spain. Ciber de enfermedades cardiovasculares (CiberCV), Luis M. Beltrán, and Raquel Rodrígues Díez
- Subjects
medicine.medical_specialty ,chemistry.chemical_compound ,Endocrinology ,Aldosterone ,Mineralocorticoid receptor ,chemistry ,business.industry ,Internal medicine ,medicine ,business ,medicine.disease ,Obesity - Published
- 2018
- Full Text
- View/download PDF
10. Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
- Author
-
Gimeno, Juan R., Olivotto, Iacopo, Isabel Rodriguez, Ana, Ho, Carolyn Y., Fernandez, Adrian, Quiroga, Alejandro, Angeles Espinosa, Mari, Gomez-Gonzalez, Cristina, Robledo, Maria, Tojal-Sierra, Lucas, Day, Sharlene M., Owens, Anjali, Barriales-Villa, Roberto, Maria Larranaga, Jose, Rodriguez-Palomares, Jose, Gonzalez-del-Hoyo, Maribel, Piqueras-Flores, Jesus, Reza, Nosheen, Chumakova, Olga, Ashley, Euan A., Parikh, Victoria, Wheeler, Matthew, Jacoby, Daniel, Pereira, Alexandre C., Saberi, Sara, Helms, Adam S., Villacorta, Eduardo, Gallego-Delgado, Maria, Castro, Daniel, Dominguez, Fernando, Ripoll-Vera, Tomas, Zorio-Grima, Esther, Carlos Sanchez-Martinez, Jose, Garcia-Alvarez, Ana, Arbelo, Elena, Victoria Mogollon, Maria, Eugenia Fuentes-Canamero, Maria, Grande, Elias, Pena, Carlos, Monserrat, Lorenzo, Lakdawala, Neal K., Dilema Int Cardiomyopathy Heart Fa, [Gimeno, Juan R.] Univ Murcia, Dept Med Interns, Ctra Finca Buenavista S-N,Campus Ciencias Salud, Murcia 30120, Spain, [Isabel Rodriguez, Ana] Univ Murcia, Dept Med Interns, Ctra Finca Buenavista S-N,Campus Ciencias Salud, Murcia 30120, Spain, [Gimeno, Juan R.] European Reference Networks Rare Low Prevalence &, Amsterdam, Netherlands, [Isabel Rodriguez, Ana] European Reference Networks Rare Low Prevalence &, Amsterdam, Netherlands, [Castro, Daniel] European Reference Networks Rare Low Prevalence &, Amsterdam, Netherlands, [Dominguez, Fernando] European Reference Networks Rare Low Prevalence &, Amsterdam, Netherlands, [Gimeno, Juan R.] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Angeles Espinosa, Mari] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Gomez-Gonzalez, Cristina] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Barriales-Villa, Roberto] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Maria Larranaga, Jose] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Rodriguez-Palomares, Jose] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Gonzalez-del-Hoyo, Maribel] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Villacorta, Eduardo] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Gallego-Delgado, Maria] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Castro, Daniel] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Dominguez, Fernando] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Zorio-Grima, Esther] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Carlos Sanchez-Martinez, Jose] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Garcia-Alvarez, Ana] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Arbelo, Elena] Ctr Biomed Network Res Cardiovasc Dis CIBERCV, Madrid, Spain, [Olivotto, Iacopo] Careggi Univ Hosp, Cardiomyopathy Unit, Florence, Italy, [Ho, Carolyn Y.] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA, [Lakdawala, Neal K.] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA, [Fernandez, Adrian] Favaloro Fdn Univ Hosp, Unidad Cardiopatias Familiares, Buenos Aires, DF, Argentina, [Quiroga, Alejandro] Favaloro Fdn Univ Hosp, Unidad Cardiopatias Familiares, Buenos Aires, DF, Argentina, [Angeles Espinosa, Mari] Hosp Gen Univ Gregorio Maranon, Unidad Cardiopatias Familiares, Madrid, Spain, [Gomez-Gonzalez, Cristina] Hosp Gen Univ Gregorio Maranon, Unidad Cardiopatias Familiares, Madrid, Spain, [Robledo, Maria] Hosp Univ Araba Txagorritxu, Alava, Spain, [Tojal-Sierra, Lucas] Hosp Univ Araba Txagorritxu, Alava, Spain, [Day, Sharlene M.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA, [Owens, Anjali] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA, [Reza, Nosheen] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA, [Barriales-Villa, Roberto] Complexo Hosp Univ A Coruna, Unidad CSUR Cardiopatias Familiares, La Coruna, Spain, [Maria Larranaga, Jose] Complexo Hosp Univ A Coruna, Unidad CSUR Cardiopatias Familiares, La Coruna, Spain, [Rodriguez-Palomares, Jose] Hosp Univ Vall dHebron, Dept Cardiol, Barcelona, Spain, [Gonzalez-del-Hoyo, Maribel] Hosp Univ Vall dHebron, Dept Cardiol, Barcelona, Spain, [Rodriguez-Palomares, Jose] Univ Autonoma Barcelona, Vall dHebron Inst Recerca VHIR, Barcelona, Spain, [Gonzalez-del-Hoyo, Maribel] Univ Autonoma Barcelona, Vall dHebron Inst Recerca VHIR, Barcelona, Spain, [Piqueras-Flores, Jesus] Hosp Gen Univ Ciudad Real, Cardiac Dept, Ciudad Real, Spain, [Chumakova, Olga] Municipal Clin Hosp 17, Moscow, Russia, [Ashley, Euan A.] Stanford Univ, Med Ctr, Ctr Inherited Heart Dis, Stanford, CA 94305 USA, [Parikh, Victoria] Stanford Univ, Med Ctr, Ctr Inherited Heart Dis, Stanford, CA 94305 USA, [Wheeler, Matthew] Stanford Univ, Med Ctr, Ctr Inherited Heart Dis, Stanford, CA 94305 USA, [Jacoby, Daniel] Yale New Haven Hosp, New Haven, CT USA, [Pereira, Alexandre C.] Univ Sao Paulo, Hosp Clin, Sao Paulo, Brazil, [Saberi, Sara] Univ Michigan Hosp, Dept Internal Med, Ann Arbor, MI 48109 USA, [Helms, Adam S.] Univ Michigan Hosp, Dept Internal Med, Ann Arbor, MI 48109 USA, [Villacorta, Eduardo] Complejo Asistencial Univ Salamanca, Serv Cardiol, Unidad Cardiopatias Familiares, Salamanca, Spain, [Gallego-Delgado, Maria] Complejo Asistencial Univ Salamanca, Serv Cardiol, Unidad Cardiopatias Familiares, Salamanca, Spain, [Villacorta, Eduardo] Inst Invest Biomed Salamanca IBSAL, Gerencia Reg Salud Castilla & Leon SACYL, Salamanca, Spain, [Gallego-Delgado, Maria] Inst Invest Biomed Salamanca IBSAL, Gerencia Reg Salud Castilla & Leon SACYL, Salamanca, Spain, [Villacorta, Eduardo] Univ Salamanca, Dept Med, Salamanca, Spain, [Gallego-Delgado, Maria] Univ Salamanca, Dept Med, Salamanca, Spain, [Castro, Daniel] Hosp Univ Puerta Hierro Majadahonda, Unidad CSUR ERN Cardiopatias Familiares, Madrid, Spain, [Dominguez, Fernando] Hosp Univ Puerta Hierro Majadahonda, Unidad CSUR ERN Cardiopatias Familiares, Madrid, Spain, [Ripoll-Vera, Tomas] Hosp Univ Son Llatzer, Unidad Cardiopatias Familiares, Mallorca, Spain, [Zorio-Grima, Esther] Hosp Univ & Politecn La Fe, Unidad Cardiopatias Familiares, Valencia, Spain, [Carlos Sanchez-Martinez, Jose] Hosp Univ & Politecn La Fe, Unidad Cardiopatias Familiares, Valencia, Spain, [Garcia-Alvarez, Ana] Univ Barcelona, Hosp Clin, Cardiol Dept, Arrhythmia Sect, Barcelona, Spain, [Arbelo, Elena] Univ Barcelona, Hosp Clin, Cardiol Dept, Arrhythmia Sect, Barcelona, Spain, [Garcia-Alvarez, Ana] Inst Invest August Pi & Sunyer IDIBAPS, Barcelona, Spain, [Arbelo, Elena] Inst Invest August Pi & Sunyer IDIBAPS, Barcelona, Spain, [Victoria Mogollon, Maria] Hosp San Pedro Alcantara, Cardiac Dept, Caceres, Spain, [Eugenia Fuentes-Canamero, Maria] Badajoz Univ Hosp, Cardiac Dept, Badajoz, Spain, [Grande, Elias] Dilemma Solut SL, La Coruna, Spain, [Pena, Carlos] Dilemma Solut SL, La Coruna, Spain, [Monserrat, Lorenzo] Dilemma Solut SL, La Coruna, SpainHosp Univ Virgen de la Victoria, Unidad Insuficiencia Cardiaca & Cardiopatias Fami, Serv Cardiol, Malaga, SpainHosp Vega Baja, Cardiac Dept, Alicante, SpainHosp Univ Virgen del Rocio, Unidad Cardiopatias Familiares, Seville, SpainUniv Trieste, Azienda Sanitaria Univ Giuliano Isontina ASUGI, Cardiothoracovasc Dept, Trieste, ItalyHosp Univ Infanta Leonor, Cardiac Dept, Madrid, SpainHosp Gen Univ Alicante, Unidad Cardiopatias Familiares, Alicante, SpainHosp Arquitecto Morcide, Cardiac Dept, Ferrol, Spain, Instituto de Salud Carlos III (ICSIII), MyoKardia/Bristol Myers Squibb, Institut Català de la Salut, [Gimeno JR] Departamento de Medicina Interna, Universidad de Murcia, Murcia, Spain. European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Amsterdam, The Netherlands. Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain. [Olivotto I] Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. [Rodríguez AI] Departamento de Medicina Interna, Universidad de Murcia, Murcia, Spain. European Reference Networks for rare, low prevalence and complex diseases of the heart (ERN GUARD-Heart), Amsterdam, The Netherlands. [Ho CY] Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA, USA. [Fernández A, Quiroga A] Unidad de Cardiopatías Familiares, Favaloro Foundation University Hospital, Buenos Aires, Argentina. [Rodríguez-Palomares J, González-del-Hoyo M] Center for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,Adult ,Registry ,Cardiology ,Heart failure ,Miocardi - Malalties - Factors de risc ,técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Ventricular Dysfunction, Left ,Atrial Fibrillation ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Humans ,Disease ,Registries ,Aged ,COVID-19 (Malaltia) - Complicacions ,SARS-CoV-2 ,SARS-CoV-2 infection ,Cor - Hipertròfia ,COVID-19 ,Cardiovascular Diseases::Heart Diseases::Cardiomyopathies::Cardiomyopathy, Hypertrophic [DISEASES] ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,Middle Aged ,Cardiomyopathy, Hypertrophic ,Prognosis ,Classification ,Hypertrophic cardiomyopathy ,enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías::miocardiopatía hipertrófica [ENFERMEDADES] ,Female ,Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Statement ,Cardiology and Cardiovascular Medicine - Abstract
COVID-19; SARS-CoV-2 infection; Heart failure COVID-19; Infección por SARS-CoV-2; Insuficiencia cardiaca COVID-19; Infecció per SARS-CoV-2; Insuficiència cardíaca Aims To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Methods and results Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12–4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75–9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16–26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20–49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98–2.91, P = 0.0600). Conclusions Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality. The project was funded by a grant from the Instituto de Salud Carlos III (ICSIII, COV20 00420). We should state that the SHaRe registry has been supported by an unrestricted grant from MyoKardia/Bristol Myers Squibb.
- Published
- 2022
- Full Text
- View/download PDF
11. Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
- Author
-
Marta Consegal, Ignasi Barba, Bruno García del Blanco, Imanol Otaegui, José F. Rodríguez-Palomares, Gerard Martí, Bernat Serra, Neus Bellera, Manuel Ojeda-Ramos, Filipa Valente, Maria Ángeles Carmona, Elisabet Miró-Casas, Antonia Sambola, Rosa María Lidón, Jordi Bañeras, José Antonio Barrabés, Cristina Rodríguez, Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Barba I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Faculty of Medicine, University of Vic - Central University of Catalonia (UVicUCC), Vic, Spain. [García Del Blanco B, Otaegui I, Rodríguez-Palomares JF, Martí G, Serra B, Bellera N, Ojeda-Ramos M, Valente F, Carmona MÁ, Miró-Casas E, Sambola A, Lidón RM, Bañeras J, Barrabés JA] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. [Ferreira-González I] Grup de Recerca de Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública, CIBERESP, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Reperfusion [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Infart de miocardi ,Multidisciplinary ,Reperfusió (Fisiologia) ,compuestos orgánicos::ácidos carboxílicos::ácidos acíclicos::ácidos dicarboxílicos::succinatos::ácido succínico [COMPUESTOS QUÍMICOS Y DROGAS] ,Organic Chemicals::Carboxylic Acids::Acids, Acyclic::Dicarboxylic Acids::Succinates::Succinic Acid [CHEMICALS AND DRUGS] ,intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::reperfusión [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] - Abstract
Cardiovascular biology; Diagnostic markers; Prognostic markers Biología cardiovascular; Marcadores de diagnóstico; Marcadores pronósticos Biologia cardiovascular; Marcadors diagnòstics; Marcadors pronòstics Succinate is enhanced during initial reperfusion in blood from the coronary sinus in ST-segment elevation myocardial infarction (STEMI) patients and in pigs submitted to transient coronary occlusion. Succinate levels might have a prognostic value, as they may correlate with edema volume or myocardial infarct size. However, blood from the coronary sinus is not routinely obtained in the CathLab. As succinate might be also increased in peripheral blood, we aimed to investigate whether peripheral plasma concentrations of succinate and other metabolites obtained during coronary revascularization correlate with edema volume or infarct size in STEMI patients. Plasma samples were obtained from peripheral blood within the first 10 min of revascularization in 102 STEMI patients included in the COMBAT-MI trial (initial TIMI 1) and from 9 additional patients with restituted coronary blood flow (TIMI 2). Metabolite concentrations were analyzed by 1H-NMR. Succinate concentration averaged 0.069 ± 0.0073 mmol/L in patients with TIMI flow ≤ 1 and was significantly increased in those with TIMI 2 at admission (0.141 ± 0.058 mmol/L, p
- Published
- 2023
- Full Text
- View/download PDF
12. Predictors of right atrial dilatation and long-term function after right ventricular outflow tract surgical repair: Quantification of restrictive physiology matters
- Author
-
Maria Antonia Pijuan-Domènech, Silvia Montserrat, Victor Pineda, Filipa Valente, Ignacio Ferreira-Gonzalez, Josep-Ramon Marsal, Miguel Angel Castro-Alba, Carlos Sureda-Barbosa, Berta Miranda-Barrio, Maria Teresa Subirana-Domènech, Laura Dos-Subirà, Jaume Casaldàliga-Ferrer, Institut Català de la Salut, [Pijuan-Domènech MA, Miranda-Barrio B, Dos-Subirà L] Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hospital Sant Pau, Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. [Montserrat S] Department of Cardiology, Cardiovascular Institute, Hospital Clinic Barcelona, Spain. [Pineda V] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Valente F] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. [Ferreira-Gonzalez I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Epidemiología CIBER-ESP, Spain. [Marsal JR] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Castro-Alba MA, Sureda-Barbosa C] Servei de Cirurgia Cardíaca, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Subirana-Domènech MT] Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hospital Sant Pau, Barcelona, Spain. Department of Cardiology, Hospital Universitari Santa Creu I Sant Pau, Barcelona, Spain. [Casaldàliga-Ferrer J] Unitat Integrada de Cardiopaties Congènites de l’Adolescent i l’Adult, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Hospital Sant Pau, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Myocardial Contraction::Diastole [PHENOMENA AND PROCESSES] ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::técnicas de imagen cardíaca::ecocardiografía [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,enfermedades cardiovasculares::enfermedades cardíacas::disfunción ventricular::disfunción ventricular derecha [ENFERMEDADES] ,fenómenos fisiológicos respiratorios y circulatorios::fenómenos fisiológicos cardiovasculares::contracción miocárdica::diástole [FENÓMENOS Y PROCESOS] ,Cardiopatia congènita ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Cardiac Imaging Techniques::Echocardiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Cardiovascular Diseases::Heart Diseases::Ventricular Dysfunction::Ventricular Dysfunction, Right [DISEASES] ,General Medicine ,intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::procedimientos quirúrgicos cardíacos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Diàstole cardíaca ,Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Cardiac Surgical Procedures [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Ecocardiografia - Abstract
Right diastolic dysfunction; Right atrium function; Restrictive physiology Disfunción diastólica derecha; Función de la aurícula derecha; Fisiología restrictiva Disfunció diastòlica dreta; Funció de l'aurícula dreta; Fisiologia restrictiva Right ventricular (RV) diastolic dysfunction in patients with a surgically-repaired RV outflow tract (RVOT) obstruction merits further studies. Right atrial (RA) dilation and function may be related to (RV) diastolic dysfunction in this setting. The end-diastolic forward flow (EDFF) in the pulmonary artery (PA) has been suggested as a non-invasive marker of poor RV compliance, however, there is controversy regarding its true significance; EDFF quantification may help elucidate this controversy. Objective to study predictors of RA enlargement and dysfunction in patients with a surgically-repaired RVOT obstruction and its relationship with quantitative EDFF. Methods In 81 consecutive patients (mean age: 37.5 (±7) years), transthoracic echocardiography (Echo) and cardiac magnetic resonance (CMR) were performed. Echo parameters: RA size (indexed RA area (iRAA)), RA function (RA global strain (RAGS)) and maximum EDFF velocity-time integral (VTI-EDFF) obtained during a whole respiratory cycle. CMR-indexed RA area (imRAA) was also obtained. Patients were divided into three groups according to iRAA, imRAA and RAGS; bivariate analysis was performed. A multivariate model was then applied using variables that were found to be statistically significant in the bivariate analysis. Results Upon multivariate analysis, higher VTI-EDFF values and the presence of significant tricuspid regurgitation proved to be independent factors associated with increased iRAA and imRAA and lower RAGS, whereas RV volumes, function and pulmonary regurgitant fraction were not. Conclusion VTI-EDFF linearly correlated with the degree of RA dilation and deformation; EDFF quantification as against qualitative assessment may be considered a non-invasive tool for diastolic RV dysfunction.
- Published
- 2023
13. Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing
- Author
-
González-Juanatey, Carlos, Anguita-Sánchez, Manuel, Barrios, Vivencio, Núñez-Gil, Iván, Gómez-Doblas, Juan José, García-Moll, Xavier, Lafuente-Gormaz, Carlos, Rollán-Gómez, María Jesús, Peral-Disdier, Vicente, Martínez-Dolz, Luis, Rodríguez-Santamarta, Miguel, Viñolas-Prat, Xavier, Soriano-Colomé, Toni, Muñoz-Aguilera, Roberto, Plaza, Ignacio, Curcio-Ruigómez, Alejandro, Orts-Soler, Ernesto, Segovia, Javier, Fanjul, Víctor, Cequier, Ángel, Savana Research Group, Institut Català de la Salut, [González-Juanatey C] Hospital Universitario Lucus Augusti, Lugo, Spain. [Anguita-Sánchez M] Hospital Universitario Reina Sofía, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain. [Barrios V] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Núñez-Gil I] Hospital Clínico Universitario San Carlos, Madrid, Spain. [Gómez-Doblas JJ] Hospital Universitario Virgen de la Victoria CIBERCV (Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares) and IBIMA (Instituto de Investigación Biomédica de Málaga), Málaga, Spain. [García-Moll X] Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. [Soriano-Colomé T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Diabetis ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Coronary Disease::Coronary Artery Disease [DISEASES] ,Diabetes ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus [ENFERMEDADES] ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedad coronaria::enfermedad arterial coronaria [ENFERMEDADES] ,General Medicine ,MACE ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [DISEASES] ,diabetes mellitus ,coronary artery disease ,risk factors ,electronic health records ,natural language processing ,Malalties coronàries - Factors de risc ,Natural language processing (Computer science) ,Investigative Techniques::Epidemiologic Methods::Data Collection::Records::Medical Records::Medical Records Systems, Computerized::Electronic Health Records [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Diabetis - Factors de risc ,Tractament del llenguatge natural (Informàtica) ,Històries clíniques - Informàtica ,técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros médicos::sistemas informatizados de historias clínicas::historias clínicas electrónicas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] - Abstract
Diabetes mellitus; Natural language processing; Risk factors Diabetis mellitus; Processament del llenguatge natural; Factors de risc Diabetes mellitus; Procesamiento del lenguaje natural; Factores de riesgo Patients with Type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD) are at high risk of developing major adverse cardiovascular events (MACE). This is a multicenter, retrospective, and observational study performed in Spain aimed to characterize these patients in a real-world setting. Unstructured data from the Electronic Health Records were extracted by EHRead®, a technology based on Natural Language Processing and machine learning. The association between new MACE and the variables of interest were investigated by univariable and multivariable analyses. From a source population of 2,184,662 patients, we identified 4072 adults diagnosed with T2DM and CAD (62.2% male, mean age 70 ± 11). The main comorbidities observed included arterial hypertension, hyperlipidemia, and obesity, with metformin and statins being the treatments most frequently prescribed. MACE development was associated with multivessel (Hazard Ratio (HR) = 2.49) and single coronary vessel disease (HR = 1.71), transient ischemic attack (HR = 2.01), heart failure (HR = 1.32), insulin treatment (HR = 1.40), and percutaneous coronary intervention (PCI) (HR = 2.27), whilst statins (HR = 0.73) were associated with a lower risk of MACE occurrence. In conclusion, we found six risk factors associated with the development of MACE which were related with cardiovascular diseases and T2DM severity, and treatment with statins was identified as a protective factor for new MACE in this study. This study was funded by AstraZeneca Spain (Externally Sponsored Scientific Research, ESR-18-13815) and sponsored by the Spanish Society of Cardiology.
- Published
- 2022
14. Evidence for reciprocal network interactions between injured hearts and cancer
- Author
-
Guler, Melisa N., Tscheiller, Nathalie M., Sabater-Molina, M. (Maria), Gimeno, Juan R., Nebigil-Désaubry, C. (Canan), Università degli studi della Campania 'Luigi Vanvitelli' = University of the Study of Campania Luigi Vanvitelli, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Nanomédecine Régénérative (NanoRegMed), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), univOAK, Archive ouverte, Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), and NEBIGIL Desaubry, Canan
- Subjects
secretoms ,[SDV]Life Sciences [q-bio] ,cardiotoxicity ,heart failure ,mechanism ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Sciences du Vivant [q-bio]/Cancer ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV] Life Sciences [q-bio] ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,inflammation ,cancer ,risk factors ,Cardiology and Cardiovascular Medicine ,bilateral interaction - Abstract
International audience; Heart failure (HF) and cancer are responsible for 50% of all deaths in middleaged people. These diseases are tightly linked, which is supported by recent epidemiological studies and case control studies, demonstrating that HF patients have a higher risk to develop cancer such as lung and breast cancer. For HF patients, a one-size-fits-all clinical management strategy is not effective and patient management represents a major economical and clinical burden. Anti-cancer treatments-mediated cardiotoxicity, leading to HF have been extensively studied. However, recent studies showed that even before the initiation of cancer therapy, cancer patients presented impairments in the cardiovascular functions and exercise capacity. Thus, the optimal cardioprotective and surveillance strategies should be applied to cancer patients with pre-existing HF. Recently, preclinical studies addressed the hypothesis that there is bilateral interaction between cardiac injury and cancer development. Understanding of molecular mechanisms of HF-cancer interaction can define the profiles of bilateral signaling networks, and identify the disease-specific biomarkers and possibly therapeutic targets. Here we discuss the shared pathological events, and some treatments of cancer-and HF-mediated risk incidence. Finally, we address the evidences on bilateral connection between cardiac injury (HF and early cardiac remodeling) and cancer through secreted factors (secretoms).
- Published
- 2022
- Full Text
- View/download PDF
15. Unraveling Bicuspid Aortic Valve Enigmas by Multimodality Imaging : Clinical Implications
- Author
-
Evangelista Masip, Arturo, Galian-Gay, Laura, Guala, Andrea, Lopez-Sainz, Angela, Teixido-Turà, Gisela, Ruiz Muñoz, Aroa, Valente, Filipa, Gutierrez, Laura, Fernandez-Galera, Ruben, Casas, Guillem, Panaro, Alejandro, Marigliano, Alba, Huguet, Marina, González-Alujas, Teresa, Rodríguez-Palomares, José F., Universitat Autònoma de Barcelona, Institut Català de la Salut, [Evangelista Masip A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Teknon Heart Institute-Quiron Salud, Barcelona, Spain. [Galian-Gay L, Guala A, Lopez-Sainz A, Teixido-Turà G, Ruiz Muñoz A, Valente F, Gutierrez L, Fernandez-Galera R, Casas G, González-Alujas T, Rodriguez-Palomares J] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
bicuspid aortic valve ,Aortic aneurysm ,Bicuspid aortic valve ,Cor - Vàlvules - Malalties - Imatgeria ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,computed tomography ,General Medicine ,Review ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades de las válvulas cardíacas [ENFERMEDADES] ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Multimodal Imaging [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Magnetic resonance imaging ,Echocardiography ,Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases [DISEASES] ,cardiovascular system ,echocardiography ,magnetic resonance imaging ,Medicine ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::imagen multimodal [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,aortic aneurysm ,Computed tomography ,Imatgeria per al diagnòstic ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] - Abstract
Aortic aneurysm; Bicuspid aortic valve; Computed tomography Aneurisma aòrtic; Vàlvula aòrtica bicúspide; Tomografia computada Aneurisma aórtico; Válvula aórtica bicúspide; Tomografía computada Multimodality imaging is the basis of the diagnosis, follow-up, and surgical management of bicuspid aortic valve (BAV) patients. Transthoracic echocardiography (TTE) is used in our clinical routine practice as a first line imaging for BAV diagnosis, valvular phenotyping and function, measurement of thoracic aorta, exclusion of other aortic malformations, and for the assessment of complications such are infective endocarditis and aortic. Nevertheless, TTE is less useful if we want to assess accurately other aortic segments such as mid-distal ascending aorta, where computed tomography (CT) and magnetic resonance (CMR) could improve the precision of aorta size measurement by multiplanar reconstructions. A major advantage of CT is its superior spatial resolution, which affords a better definition of valve morphology and calcification, accuracy, and reproducibility of ascending aorta size, and allows for coronary artery assessment. Moreover, CMR offers the opportunity of being able to evaluate aortic functional properties and blood flow patterns. In this setting, new developed sequences such as 4D-flow may provide new parameters to predict events during follow up. The integration of all multimodality information facilitates a comprehensive evaluation of morphologic and dynamic features, stratification of the risk, and therapy guidance of this cohort of patients.
- Published
- 2022
16. Dynamics of Emergency Cardiovascular Hospital Admissions and In-Hospital Mortality During the COVID-19 Pandemic: Time Series Analysis and Impact of Socioeconomic Factors
- Author
-
Claudia Álvarez-Martín, Aida Ribera, Josep Ramon Marsal, Albert Ariza-Solé, Santiago Pérez-Hoyos, Gerard Oristrell, Toni Soriano-Colomé, Rafael Romaguera, Jose Ignacio Pijoan, Rosa M. Lidón, Josepa Mauri, Ignacio Ferreira-González, Institut Català de la Salut, [Álvarez-Martín C, Marsal JR] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Ribera A] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Recerca en Envelliment, Fragilitat i Transicions (REFiT) Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d’Hebron Institute of Research, Barcelona, Spain. [Ariza-Solé A] Cardiology Department, Hospital Universitari de Bellvitge, Barcelona, Spain. Bioheart, Grup de Malalties Cardiovasculars, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain. Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Pérez-Hoyos S] Unitat d'Estadística i Bioinformàtica (UEB), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Statistics Department, Faculty of Biology, University of Barcelona, Barcelona, Spain. [Oristrell G, Lidón RM] Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Soriano-Colomé T] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferreira-González I] Unitat de Recerca Cardiovascular i Epidemiologia, Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad [Otros calificadores] ,Cardiovascular Diseases [DISEASES] ,epidemiología y bioestadística::bioestadística::datos demográficos::estadísticas vitales::mortalidad::mortalidad hospitalaria [SALUD PÚBLICA] ,Cardiac patients ,COVID-19 ,Heart failure ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,COVID-19 (Malaltia) ,Epidemiology and Biostatistics::Biostatistics::Demographic Data::Vital Statistics::Mortality::Hospital Mortality [PUBLIC HEALTH] ,Malalts cardíacs ,Myocardial infarction ,Economic conditions ,Mortalitat - Estadístiques ,Other subheadings::Other subheadings::Other subheadings::/mortality [Other subheadings] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Condicions econòmiques ,Acute coronary syndrome ,Time-series ,Cardiology and Cardiovascular Medicine ,Sistema cardiovascular - Malalties - Mortalitat ,enfermedades cardiovasculares [ENFERMEDADES] - Abstract
COVID-19; Síndrome coronario agudo; Insuficiencia cardiaca COVID-19; Síndrome coronària aguda; Insuficiència cardíaca COVID-19; Acute coronary syndrome; Heart failure Aims: This study aimed to evaluate the decline in urgent cardiovascular hospital admissions and in-hospital mortality during the COVID pandemic in two successive waves, and to evaluate differences by sex, age, and deprivation index subgroups. Methods and Results: We obtained acute cardiovascular hospital episodes during the years 2019–2020 from region-wide data on public healthcare usage for the population of Catalonia (North-East Spain). We fitted time models to estimate the incidence rate ratios (IRRs) of the acute coronary syndrome (ACS) and acute heart failure (HF) admissions during the first pandemic wave, the between-waves period, and the second wave compared with the corresponding pre-COVID-19 periods and to test for the interaction with sex, age, and area-based socioeconomic level. We evaluated the effect of COVID-19 period on in-hospital mortality. ACS (n = 8,636) and HF (n = 27,566) episodes were defined using primary diagnostic ICD-10 codes. ACS and HF admissions decreased during the first wave (IRR = 0.66, 95%CI: 0.58–0.76 and IRR = 0.61, 95% CI: 0.55–0.68, respectively) and during the second wave (IRR = 0.80, 95%CI: 0.72–0.88 and IRR = 0.76, 95%CI: 0.69–0.84, respectively); acute HF admissions also decreased in the period between waves (IRR: 0.81, 95%CI: 0.74–0.89). The impact was similar in all sex and socioeconomic subgroups and was higher in older patients with ACS. In-hospital mortality was higher than expected only during the first wave. Conclusion: During the first wave of the COVID-19 pandemic, there was a marked decline in urgent cardiovascular hospital admissions that were attenuated during the second wave. Both the decline and the attenuation of the effect have been similar in all subgroups regardless of age, sex, or socioeconomic status. In-hospital mortality for ACS and HF episodes increased during the first wave, but not during the second wave. This study was funded with a grant from Sociedad Española de Cardiología y Fundación Española del Corazón (SEC/FEC-INV-CLI 21/017). The funder had no role in the study development.
- Published
- 2022
17. Predictors of Ascending Aorta Enlargement and Valvular Dysfunction Progression in Patients with Bicuspid Aortic Valve
- Author
-
José Rodríguez-Palomares, Sergio Moral, María Celeste Carrero, Laura Galian, Rodolfo Citro, Laura Gutierrez, Josep M. Alegret, Ilaria Dentamaro, Arturo Evangelista, Francisco Calvo, Antonella Moreo, Violeta Sánchez, Paolo Colonna, Augusto Sao-Aviles, Gisela Teixido-Tura, Angela Lopez, Eduardo Bossone, Fabio Chirillo, Institut Català de la Salut, [Lopez A, Dentamaro I, Galian L, Sao-Aviles A, Gutiérrez L, Teixido-Tura G, Rodríguez-Palomares J] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain. [Calvo F] Cardiology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. [Alegret JM] Cardiology Department, Hospital Universitari Sant Joan de Reus, IISPV, Universitat Rovira i Virgili, Reus, Spain. [Sanchez V] Cardiology Department, University Hospital 12 de Octubre, Madrid, Spain. [Evangelista A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain. Heart Institute, Teknon Medical Center-Quirón Salud, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Lopez, A., Dentamaro, I., Galian, L., Calvo, F., Alegret, J. M., Sanchez, V., Citro, R., Moreo, A., Chirillo, F., Colonna, P., Carrero, M. C., Bossone, E., Moral, S., Sao-Aviles, A., Gutierrez, L., Teixido-Tura, G., Rodriguez-Palomares, J., and Evangelista, A.
- Subjects
Aortic valve ,Pathological Conditions, Signs and Symptoms::Pathological Conditions, Anatomical::Dilatation, Pathologic [DISEASES] ,medicine.medical_specialty ,Aortic stenosi ,bicuspid aortic valve ,Regurgitation (circulation) ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades de las válvulas cardíacas [ENFERMEDADES] ,Article ,Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores] ,Bicuspid aortic valve ,Aneurysm ,Internal medicine ,medicine.artery ,Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases::Aortic Valve Insufficiency [DISEASES] ,Ascending aorta ,medicine ,Outpatient clinic ,afecciones patológicas, signos y síntomas::afecciones patológicas anatómicas::dilatación patológica [ENFERMEDADES] ,business.industry ,aortic stenosis ,General Medicine ,Cor - Vàlvules - Malalties - Complicacions ,medicine.disease ,Insuficiència aòrtica ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades de las válvulas cardíacas::insuficiencia de la válvula aórtica [ENFERMEDADES] ,aortic regurgitation ,Stenosis ,medicine.anatomical_structure ,Cardiology ,Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases [DISEASES] ,cardiovascular system ,aneurysm ,Vasos sanguinis - Dilatació ,Medicine ,business ,Dyslipidemia ,Other subheadings::Other subheadings::/complications [Other subheadings] - Abstract
Bicuspid aortic valve (BAV) patients are at high risk of developing progressive aortic valve dysfunction and ascending aorta dilation. However, the progression of the disease is not well defined. We aimed to assess mid-long-term aorta dilation and valve dysfunction progression and their predictors. Patients were referred from cardiac outpatient clinics to the echocardiographic laboratories of 10 tertiary hospitals and followed clinically and by echocardiography for >, 5 years. Seven hundred and eighteen patients with BAV (median age 47.8 years [IQR 33–62], 69.2% male) were recruited. BAV without raphe was observed in 11.3%. After a median follow-up of 7.2 years [IQR5–8], mean aortic root growth rate was 0.23 ± 0.15 mm/year. On multivariate analysis, rapid aortic root dilation (>, 0.35 mm/year) was associated with male sex, hypertension, presence of raphe and aortic regurgitation. Annual ascending aorta growth rate was 0.43 ± 0.32 mm/year. Rapid ascending aorta dilation was related only to hypertension. Variables associated with aortic stenosis and regurgitation progression, adjusted by follow-up time, were presence of raphe, hypertension and dyslipidemia and basal valvular dysfunction, respectively. Intrinsic BAV characteristics and cardiovascular risk factors were associated with aorta dilation and valvular dysfunction progression, taking into account the inherent limitations of our study-design. Strict and early control of cardiovascular risk factors is mandatory in BAV patients.
- Published
- 2021
- Full Text
- View/download PDF
18. Are Aortic Root and Ascending Aorta Diameters Measured by the Pediatric versus the Adult American Society of Echocardiography Guidelines Interchangeable?
- Author
-
Ignacio Ferreira, Laura Galian-Gay, Maria Luz Servato, Gisela Teixido-Tura, Laura Gutierrez, Rubén Fernández-Galera, Filipa Valente, Guillem Casas, Anna Sabaté-Rotés, Arturo Evangelista, Ángela López-Sainz, M. Teresa González-Alujas, José Rodríguez-Palomares, Augusto Sao-Aviles, Institut Català de la Salut, [Servato ML, Teixidó-Turá G, Galian-Gay L, Gutiérrez L, Valente F, Fernandez-Galera R, Casas G, López-Sainz A, González-Alujas MT, Sao-Aviles A, Ferreira I, Rodríguez-Palomares J] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain. [Sabate-Rotes A] Servei de Cardiologia Pediàtrica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain. [Evangelista A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBERCV, Barcelona, Spain. Teknon Medical Center-Quirón Salud, Heart Institute, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
medicine.medical_specialty ,aortic dimensions ,Aortic root ,Population ,Diastole ,Sistema cardiovascular - Malalties ,Aortic disease ,Article ,Internal medicine ,medicine.artery ,Ascending aorta ,medicine ,echocardiography ,education ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,enfermedades cardiovasculares [ENFERMEDADES] ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::técnicas de imagen cardíaca::ecocardiografía [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Aorta ,education.field_of_study ,Cardiovascular Diseases [DISEASES] ,business.industry ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Cardiac Imaging Techniques::Echocardiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,guideline’s recommendations ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,General Medicine ,Cardiovascular System::Blood Vessels::Arteries::Aorta [ANATOMY] ,Clinical Practice ,Aorta - Malalties - Imatgeria per ressonància magnètica ,aorta ,Cardiology ,cardiovascular system ,Medicine ,Aorta diameter ,business ,sistema cardiovascular::vasos sanguíneos::arterias::aorta [ANATOMÍA] ,Ecocardiografia - Abstract
Ascending aorta diameters have important clinical value in the diagnosis, follow-up, and surgical indication of many aortic diseases. However, there is no uniformity among experts regarding ascending aorta diameter quantification by echocardiography. The aim of this study was to compare maximum aortic root and ascending aorta diameters determined by the diastolic leading edge (DLE) and the systolic inner edge (SIE) conventions in adult and pediatric patients with inherited cardiovascular diseases. Transthoracic echocardiograms were performed in 328 consecutive patients (260 adults and 68 children). Aorta diameters were measured twice at the root and ascending aorta by the DLE convention following the 2015 American Society of Echocardiography (ASE) adult guidelines and the SIE convention following the 2010 ASE pediatric guidelines. Comparison of the diameters measured by the two conventions in the overall population showed a non-significant underestimation of the diameter measured by the SIE convention at root level of 0.28 mm (CI -1.36, 1.93) and at tubular ascending aorta level of 0.17 mm (CI-1.69, 2.03). Intraobserver and interobserver variability were excellent. Maximum aorta diameter measured by the leading edge convention in end-diastole and the inner edge convention in mid-systole had similar values to a mild non-significant underestimation of the inner-to-inner method that permits them to be interchangeable when used in clinical practice.
- Published
- 2021
19. Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome
- Author
-
Gonzalo Luis Alonso Salinas, Sergio Raposeiras-Roubín, Alberto Cordero, Francisco Marcos Marín, Pablo Díez-Villanueva, Manuel Martínez-Sellés, Eduardo Núñez, Alfredo Bardají, Albert Ariza-Solé, Nuria Vicente-Ibarra, Juan M. Ruiz-Nodar, Juan Sanchis, Belén Cid-Álvarez, José María García-Acuña, Julio Núñez, Emad Abu Assi, F Formiga, José A. Barrabés, Institut Català de la Salut, [Díez-Villanueva P] Servicio de Cardiología, Hospital Universitario La Princesa, Madrid, Spain. [García-Acuña JM] Servicio de Cardiología, Hospital Clínico Universitario de Santiago, CIBERCV, Santiago de Compostela, A Coruña, Spain. [Raposeiras-Roubin S] Servicio de Cardiología, Hospital Álvaro Cunqueiro de Vigo, Vigo, Pontevedra, Spain. [Barrabés JA] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERCV, Barcelona, Spain. [Cordero A] Servicio de Cardiología, Hospital Clínico Universitario de San Juan, Alicante, Spain. [Martínez-Sellés M] Servicio de Cardiología, Hospital Universitario Gregorio Marañón, CIBERCV, Universidad Europea, Universidad Complutense, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Acute coronary syndrome ,medicine.medical_specialty ,Anemia ,Mujer ,medicine.medical_treatment ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus [ENFERMEDADES] ,Enfermedad cardiovascular ,Anciano ,Otros calificadores::/diagnóstico [Otros calificadores] ,Dones ,Dietética y nutrición ,Disease ,Malalties coronàries ,Revascularization ,elderly ,Article ,Coronary diseases ,Infarto del miocardio sin elevación del ST ,non-ST-segment elevation acute coronary syndromes ,Diabetes mellitus ,Internal medicine ,Other subheadings::/diagnosis [Other subheadings] ,medicine ,Clinical endpoint ,Endocrinología ,Women ,Diagnosis::Prognosis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Diabetis - Prognosi ,diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Diabetis ,business.industry ,ST elevation ,Diabetes ,General Medicine ,medicine.disease ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [DISEASES] ,Diabetes mellitus tipo 2 ,diabetes mellitus ,Diferències entre sexes ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::síndrome coronario agudo [ENFERMEDADES] ,Medicine ,women ,business ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Acute Coronary Syndrome [DISEASES] ,Kidney disease - Abstract
Few studies have addressed to date the interaction between sex and diabetes mellitus (DM) in the prognosis of elderly patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Our aim was to address the role of DM in the prognosis of non-selected elderly patients with NSTEACS according to sex. A retrospective analysis from 11 Spanish NSTEACS registries was conducted, including patients aged ≥70 years. The primary end point was one-year all-cause mortality. A total of 7211 patients were included, 2,770 (38.4%) were women, and 39.9% had DM. Compared with the men, the women were older (79.95 ± 5.75 vs. 78.45 ± 5.43 years, p <, 0.001) and more often had a history of hypertension (77% vs. 83.1%, p <, 0.01). Anemia and chronic kidney disease were both more common in women. On the other hand, they less frequently had a prior history of arteriosclerotic cardiovascular disease or comorbidities such as peripheral artery disease and chronic pulmonary disease. Women showed a worse clinical profile on admission, though an invasive approach and in-hospital revascularization were both more often performed in men (p <, 0.001). At a one-year follow-up, 1090 patients (15%) had died, without a difference between sexes. Male sex was an independent predictor of mortality (HR = 1.15, 95% CI 1.01 to 1.32, p = 0.035), and there was a significant interaction between sex and DM (p = 0.002). DM was strongly associated with mortality in women (HR: 1.45, 95% CI = 1.18–1.78, p <, 0.001), but not in men (HR: 0.98, 95% CI = 0.84–1.14, p = 0.787). In conclusion, DM is associated with mortality in older women with NSTEACS, but not in men.
- Published
- 2021
20. The valve uptake index: improving assessment of prosthetic valve endocarditis and updating [18F]FDG PET/CT(A) imaging criteria
- Author
-
Albert Roque, María N Pizzi, Nuria Fernández-Hidalgo, Guillermo Romero-Farina, Gemma Burcet, José Luis Reyes-Juarez, Carina Espinet, Joan Castell-Conesa, Manuel Escobar, Ignacio Ferreira-González, Santiago Aguadé-Bruix, Hug Cuellar-Calabria, Institut Català de la Salut, [Roque A, Burcet G, Reyes-Juarez JL, Cuellar-Calabria H] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Pizzi MN] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Fernández-Hidalgo N] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Romero-Farina G] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Espinet C, Castell-Conesa J] IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Escobar M] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. IDI (Institut de Diagnòstic per la Imatge), Barcelona, Spain. [Ferreira-González I] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Epidemiologıa y Salud Pública (CIBERESP), Madrid, Spain. [Aguadé-Bruix S] Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Endocarditis bacteriana - Imatgeria ,Pròtesis valvulars cardíaques ,Prosthesis-Related Infections ,Endocarditis ,infecciones bacterianas y micosis::infección::infecciones relacionadas con prótesis [ENFERMEDADES] ,diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada por rayos X::angiografía por tomografía computarizada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,General Medicine ,Endocarditis, Bacterial ,Fluorodeoxyglucose F18 ,Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, X-Ray Computed::Computed Tomography Angiography [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Heart Valve Prosthesis ,Positron Emission Tomography Computed Tomography ,Cardiovascular Diseases::Heart Diseases::Endocarditis [DISEASES] ,Bacterial Infections and Mycoses::Infection::Prosthesis-Related Infections [DISEASES] ,Humans ,Radiology, Nuclear Medicine and imaging ,Tomografia per emissió de positrons ,enfermedades cardiovasculares::enfermedades cardíacas::endocarditis [ENFERMEDADES] ,Radiopharmaceuticals ,Cardiology and Cardiovascular Medicine ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,Retrospective Studies - Abstract
Aims Diagnosis of prosthetic valve endocarditis (PVE) by positron emission computed tomography angiography (PET/CTA) is based on visual and quantitative morpho-metabolic features. However, the fluorodeoxyglucose (FDG) uptake pattern can be sometimes visually unclear and susceptible to subjectivity. This study aimed to validate a new parameter, the valve uptake index [VUI, maximum standardized uptake value (SUVmax)−mean standardized uptake value (SUVmean)/SUVmax], designed to provide a more objective indication of the distribution of metabolic activity. Secondly, to re-evaluate the utility of traditionally used PVE imaging criteria and determine the potential value of adding the VUI in the diagnostic algorithm of PVE. Methods and results Retrospective analysis of 122 patients (135 prosthetic valves) admitted for suspicion of endocarditis, with a conclusive diagnosis of definite (N = 57) or rejected (N = 65) PVE, and who had undergone a cardiac PET/CTA scan as part of the diagnostic evaluation. We measured the VUI and recorded the SUVmax, SUVratio, uptake pattern, and the presence of endocarditis-related anatomic lesions. The VUI, SUVmax, and SUVratio values were 0.54 ± 0.1 vs. 0.36 ± 0.08, 7.68 ± 3.07 vs. 3.72 ± 1.11, and 4.28 ± 1.93 vs. 2.16 ± 0.95 in the ‘definite’ PVE group vs. the ‘rejected’ group, respectively (mean ± SD; P < 0.001). A cut-off value of VUI > 0.45 showed a sensitivity, specificity, and diagnostic accuracy for PVE of 85%, 88%, and 86.7% and increased diagnostic ability for confirming endocarditis when combined with the standard diagnostic criteria. Conclusions The VUI demonstrated good diagnostic accuracy for PVE, even increasing the diagnostic power of the traditionally used morphometabolic parameters, which also confirmed their own diagnostic performance. More research is needed to assess whether the integration of the VUI into the PVE diagnostic algorithm may clarify doubtful cases and thus improve the diagnostic yield of PET/CTA.
- Published
- 2021
21. Comprehensive Long-Term Follow up of Adults with Arterial Switch Operation – European Collaboration for Prospective Outcome Research in Congenital Heart disease (EPOCH-ASO)–Study Design and Protocols
- Author
-
Judith Bouchardy, Berto J. Bouma, Pastora Gallego, Harald Gabriel, Daniel Tobler, Laura Dos, Joaquín Rueda Soriano, Matthias Greutmann, Markus Schwerzmann, Magalie Ladouceur, Francisco Javier Ruperti-Repilado, Cardiology, ACS - Heart failure & arrhythmias, ACS - Pulmonary hypertension & thrombosis, [Ruperti-Repilado, Francisco Javier] Univ Bern, Univ Hosp, Ctr Congenital Heart Dis, Inselspital,Cardiol, Bern, Switzerland, [Schwerzmann, Markus] Univ Bern, Univ Hosp, Ctr Congenital Heart Dis, Inselspital,Cardiol, Bern, Switzerland, [Ladouceur, Magalie] Univ Paris, Hop Europeen Georges Pompidou, AP HP,Adult Congenital Heart Dis Unit,M3C Inserm, Paris Ctr Rech Cardiovasc,Ctr Reference Malformat, Paris, France, [Gallego, Pastora] Hosp Univ Virgen del Rocio, Adult Congenital Heart Dis Unit, Dept Cardiol, Inst BioMed Sevilla, Seville, Spain, [Gallego, Pastora] CIBERCV, Seville, Spain, [Dos, Laura] Hosp Univ Vall dHebron, Unitat Cardiopaties Congenites Adolescent & Adult, Barcelona, Spain, [Rueda Soriano, Joaquin] Hosp Univ & Politecn La Fe, Adult Congenital Heart Dis Unit, Dept Cardiol, Valencia, Spain, [Rueda Soriano, Joaquin] CIBERCV, Valencia, Spain, [Bouma, Berto] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands, [Gabriel, Harald] Med Univ Vienna, Dept Cardiol, Adult Congenital Heart Dis Program, Vienna, Austria, [Bouchardy, Judith] Univ Hosp Lausanne, Dept Cardiol & Cardiac Surg, Lausanne, Switzerland, [Bouchardy, Judith] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland, [Tobler, Daniel] Univ Basel, Univ Hosp Basel, Div Cardiol, Basel, Switzerland, [Greutmann, Matthias] Univ Zurich, Univ Heart Ctr, Dept Cardiol, Zurich, Switzerland, and EPOCH-ASO
- Subjects
Pediatrics ,medicine.medical_specialty ,Heart disease ,Quality of life ,Transposition ,medicine ,Aortic root ,Transposition of the great arteries ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,Stroke ,American society ,Opposite sinus ,business.industry ,coronary artery anomaly ,General Medicine ,Coronary-arteries ,medicine.disease ,Ventricular septal-defect ,Stenosis ,Anatomic repair ,Heart failure ,Pediatrics, Perinatology and Child Health ,Cohort ,outcome ,cardiovascular system ,Great-arteries ,Surgery ,Quality-of-life ,Pulmonary stenosis ,Cardiology and Cardiovascular Medicine ,business ,arterial switch operation ,Cohort study - Abstract
Background: Long-term outcomes in adults with prior arterial switch operation (ASO) have not yet been well defined. The aim of this study is to elucidate incidence and predictors of adverse cardiac outcomes in a prospectively followed cohort of adults after their ASO. Methods: The comprehensive long-term follow up of adults with ASO is a project within the European collaboration for prospective outcome research in congenital heart disease (EPOCH). It is designed as a prospective, international multicenter cohort study. Consecutive patients (age ≥ 16 years) with prior ASO will be included at 11 European tertiary care centers. Participants will be followed according to a standardized protocol following international recommendations, including standardized protocols for imaging and for exercise testing. Results: Main outcome measures are all-cause and cardiac-related mortality, rate of cardiac re-intervention, neo-aortic dissection, myocardial infarction, stroke, infective endocarditis, sustained atrial and ventricular arrhythmias, new-onset or worsening pulmonary hypertension or heart failure. Secondary endpoints are frequency and progression of right ventricular outflow stenosis, neo-aortic root dilatation, neo-aortic valve regurgitation and ventricular dysfunction. The impact of demographic, anatomic (e.g., coronary artery anato-my) and functional variables on the above-mentioned outcomes, as well as quality of life and incidence of pregnancy related complications will also be assessed. Conclusion: The prospective, international, multicenter EPOCH-ASO study will provide a better understanding of adverse outcomes and their predictors in adults after ASO. The results of the EPOCH-ASO study may help to optimize future care of this novel patient cohort in adult cardiology.
- Published
- 2020
- Full Text
- View/download PDF
22. Deletion of the Wilms' Tumor Suppressor Gene in the Cardiac Troponin-T Lineage Reveals Novel Functions of WT1 in Heart Development
- Author
-
Sandra Díaz del Moral, Silvia Barrena, Francisco Hernández-Torres, Amelia Aránega, José Manuel Villaescusa, Juan José Gómez Doblas, Diego Franco, Manuel Jiménez-Navarro, Ramón Muñoz-Chápuli, Rita Carmona, [Díaz del Moral,S, Barrena,S, Muñoz-Chápuli,R, Carmona,R] Department of Animal Biology, University of Málaga, Málaga, Spain. [Hernández-Torres,F] Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, Granada, Spain. [Hernández-Torres,F, Aránega,A] Medina Foundation, Technology Park of Health Sciences, Granada, Spain. [Aránega,A, Franco,D] Department of Experimental Biology, Faculty of Experimental Sciences, University of Jaén, Jaén, Spain. [Villaescusa,JM, Gómez Doblas,JJ, Jiménez-Navarro,M] Heart Area Clinical Management Unit, University Hospìtal Virgen de la Victoria, CIBERCV Enfermedades Cardiovasculares Health Institute Carlos III, Biomedical Research Institute of Malaga (IBIMA), University of Málaga, Málaga, Spain., and This work was supported by: Spanish Ministry of Economy, Industry and Competitivity (BFU2017-83907-P to RM-C and RC and PID2019-107492GB-I00 to AA and DF), Consejería de Salud, Junta de Andalucía (PC0066?2017/PC-0081-2017 to RC, JV, and JG), Instituto de Salud Carlos III-TERCEL network (RD16/0011/0030 to RM-C and RC), Instituto de Salud Carlos III-CIBERCV 'Enfermedades Cardiovasculares' (CB16/11/00360 to MJ-N), and Consejería de Economía yConocimiento, Junta de Andalucía (UMA18-FEDERJA-146 to RM-C and RC and FEDER-UJA to AA and DF).
- Subjects
0301 basic medicine ,Pathology ,Genes supresores de tumores ,TNNT2 ,cardiac development ,Canales de potasio ,cardiomyocytes ,Genes del tumor de Wilms ,0302 clinical medicine ,Calcium homeostasis ,Homeostasis ,Wilms’ tumor suppressor gene ,Atrium (heart) ,Biology (General) ,Anatomy::Cardiovascular System::Heart::Pericardium [Medical Subject Headings] ,Original Research ,Cardiomyocytes ,Anatomy::Musculoskeletal System::Muscles::Myocardium [Medical Subject Headings] ,Heart development ,calcium homeostasis ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Membrane Transport Proteins::Ion Channels::Potassium Channels [Medical Subject Headings] ,potassium channels ,Chemicals and Drugs::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Calcium [Medical Subject Headings] ,medicine.anatomical_structure ,Chemicals and Drugs::Macromolecular Substances::Polymers::Biopolymers::Microfilament Proteins::Troponin::Troponin T [Medical Subject Headings] ,cardiovascular system ,Crecimiento y desarrollo ,medicine.medical_specialty ,QH301-705.5 ,Biology ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Transcription Factors [Medical Subject Headings] ,Pectinate muscles ,Potassium channels ,03 medical and health sciences ,QRS complex ,Cell and Developmental Biology ,Calcio ,Cardiac development ,medicine ,Interventricular septum ,cardiovascular diseases ,Sinus venosus ,Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes, Recessive::Genes, Tumor Suppressor [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings] ,Wilms' tumor ,Cell Biology ,medicine.disease ,Wilms' tumor supressor gene ,030104 developmental biology ,Diseases::Neoplasms::Neoplastic Syndromes, Hereditary::Wilms Tumor [Medical Subject Headings] ,Anatomy::Cardiovascular System::Heart::Myocardium::Myocytes, Cardiac [Medical Subject Headings] ,Miocitos cardíacos ,030217 neurology & neurosurgery ,Developmental Biology - Abstract
This work was supported by: Spanish Ministry of Economy, Industry and Competitivity (BFU2017-83907-P to RM-C and RC and PID2019-107492GB-I00 to AA and DF), Consejeria de Salud, Junta de Andalucia (PC0066?2017/PC-0081-2017 to RC, JV, and JG), Instituto de Salud Carlos III-TERCEL network (RD16/0011/0030 to RM-C and RC), Instituto de Salud Carlos III-CIBERCV "Enfermedades Cardiovasculares" (CB16/11/00360 to MJ-N), and Consejeria de Economia y Conocimiento, Junta de Andalucia (UMA18-FEDERJA-146 to RM-C and RC and FEDER-UJA to AA and DF)., Expression of Wilms’ tumor suppressor transcription factor (WT1) in the embryonic epicardium is essential for cardiac development, but its myocardial expression is little known. We have found that WT1 is expressed at low levels in 20–25% of the embryonic cardiomyocytes. Conditional ablation of WT1 using a cardiac troponin T driver (Tnnt2Cre) caused abnormal sinus venosus and atrium development, lack of pectinate muscles, thin ventricular myocardium and, in some cases, interventricular septum and cardiac wall defects, ventricular diverticula and aneurisms. Coronary development was normal and there was not embryonic lethality, although survival of adult mutant mice was reduced probably due to perinatal mortality. Adult mutant mice showed electrocardiographic anomalies, including increased RR and QRS intervals, and decreased PR intervals. RNASeq analysis identified differential expression of 137 genes in the E13.5 mutant heart as compared to controls. GO functional enrichment analysis suggested that both calcium ion regulation and modulation of potassium channels are deeply altered in the mutant myocardium. In summary, together with its essential function in the embryonic epicardium, myocardial WT1 expression is also required for normal cardiac development., Spanish Ministry of Economy, Industry and Competitivity BFU2017-83907-P PID2019-107492GB-I00, Junta de Andalucia PC0066?2017/PC-0081-2017, Instituto de Salud Carlos III-TERCEL network RD16/0011/0030 Instituto de Salud Carlos III-CIBERCV "Enfermedades Cardiovasculares" CB16/11/00360, Junta de Andalucia UMA18-FEDERJA-146
- Published
- 2021
23. Non-Coding RNAs in Kidney Diseases: The Long and Short of Them
- Author
-
Melania Guerrero-Hue, Valérie Metzinger-Le Meuth, Eya Hamza, Cristina García-Caballero, Sandra Rayego-Mateos, Juan Antonio Moreno, Laurent Metzinger, Mercedes Vallejo-Mudarra, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), [Moreno,JA, Guerrero-Hue,M, García-Caballero,C, Vallejo-Mudarra,M] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), UGC Nephrology, Hospital Universitario Reina Sofía, Córdoba, Spain. [Moreno,JA] Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain. [Moreno,JA] Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain. [Hamza,E, Metzinger,L, Metzinger-Le Meuth,V] HEMATIM UR 4666, C.U.R.S, Université de Picardie Jules Verne (UPJV), CEDEX 1, Amiens, France. [Rayego-Mateos,S] Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. [Metzinger-Le Meuth,V] INSERM UMRS 1148, Laboratory for Vascular Translational Science (LVTS), UFR SMBH, Université Sorbonne Paris Nord, CEDEX, Bobigny, France., This research was funded by SFNDT, Vifor. (L.M., V.M.-L.M. and E.H.), Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130 and PI20/00375), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017-22369), and Spanish Society of Nephrology (SEN). The 'PFIS' and 'Sara Borrell' training program of the ISCIII supported the salary of MGH (FI18/00310) and SR-M (CD19/00021)., Hospital Universitario Reina Sofia [Cordoue, Espagne], Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), Universidad de Córdoba = University of Córdoba [Córdoba], HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Universidad Autónoma de Madrid (UAM), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, and DESSAIVRE, Louise
- Subjects
[SDV]Life Sciences [q-bio] ,Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation [Medical Subject Headings] ,Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::Oligonucleotides, Antisense [Medical Subject Headings] ,non-coding RNA ,Review ,Genome ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Chronic kidney disease ,Acute kidney disease ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,Insuficiencia renal crónica ,Biology (General) ,Spectroscopy ,Regulation of gene expression ,MicroARNs ,Kidney ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic [Medical Subject Headings] ,long non-coding RNA ,microRNA ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases [Medical Subject Headings] ,General Medicine ,IgA nephropathy ,Non-coding RNA ,Long non-coding RNA ,Computer Science Applications ,[SDV] Life Sciences [q-bio] ,Chemistry ,medicine.anatomical_structure ,Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Urologic Diseases::Kidney Diseases [Medical Subject Headings] ,RNA, Long Noncoding ,acute kidney disease ,ARN largo no codificante ,Glomerulonefritis por IgA ,ARN no traducido ,Medicina ,QH301-705.5 ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics [Medical Subject Headings] ,Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Untranslated::RNA, Long Noncoding [Medical Subject Headings] ,Computational biology ,Biology ,Catalysis ,Inorganic Chemistry ,Enfermedades renales ,Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings] ,medicine ,Animals ,Humans ,RNA, Messenger ,Physical and Theoretical Chemistry ,Renal Insufficiency, Chronic ,QD1-999 ,Molecular Biology ,Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::DNA, Intergenic [Medical Subject Headings] ,Organic Chemistry ,RNA ,Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Messenger [Medical Subject Headings] ,Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics [Medical Subject Headings] ,Noncoding DNA ,Gene regulation ,MicroRNAs ,Regulación de la expresión génica ,Gene Expression Regulation ,gene regulation ,chronic kidney disease - Abstract
Recent progress in genomic research has highlighted the genome to be much more transcribed than expected. The formerly so-called junk DNA encodes a miscellaneous group of largely unknown RNA transcripts, which contain the long non-coding RNAs (lncRNAs) family. lncRNAs are instrumental in gene regulation. Moreover, understanding their biological roles in the physiopathology of many diseases, including renal, is a new challenge. lncRNAs regulate the effects of microRNAs (miRNA) on mRNA expression. Understanding the complex crosstalk between lncRNA– miRNA–mRNA is one of the main challenges of modern molecular biology. This review aims to summarize the role of lncRNA on kidney diseases, the molecular mechanisms involved, and their function as emerging prognostic biomarkers for both acute and chronic kidney diseases. Finally, we will also outline new therapeutic opportunities to diminish renal injury by targeting lncRNA with antisense oligonucleotides., This research was funded by SFNDT, Vifor. (L.M., V.M.-L.M. and E.H.), Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130 and PI20/00375), Spanish Biomedical Research Centre in Cardiovascular Diseases (CIBERCV), Spanish Ministry of Science and Innovation (RYC-2017-22369), and Spanish Society of Nephrology (SEN). The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310) and SR-M (CD19/00021). Córdoba University supported the salary of C.G.C.
- Published
- 2021
- Full Text
- View/download PDF
24. Citric Acid Cycle Metabolites Predict Infarct Size in Pigs Submitted to Transient Coronary Artery Occlusion and Treated with Succinate Dehydrogenase Inhibitors or Remote Ischemic Perconditioning
- Author
-
Begoña Benito, Marisol Ruiz-Meana, Javier Inserte, Norberto Núñez, Marta Consegal, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas, Ignasi Barba, Institut Català de la Salut, [Consegal M, Benito B, Ruiz-Meana M, Inserte J, Rodríguez-Sinovas A] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Núñez N] Unitat d'Alta Tecnologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Barba I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 28029 Madrid, Spain. Faculty of Medicine, University of Vic-Central University of Catalonia (UVicUCC), Can Baumann. Ctra. de Roda, 70, 08500 Vic, Spain. [Ferreira-González I] Grup de Recerca en Malalties Cardiovasculars, Servei de Cardiologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red (CIBER) de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Swine ,Endogeny ,030204 cardiovascular system & hematology ,Pharmacology ,ischemia-reperfusion ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Dicarboxylic Acids ,Myocardial infarction ,Biology (General) ,Enzyme Inhibitors ,Ischemic Preconditioning ,Spectroscopy ,remote ischemic conditioning ,biology ,Àcid cítric - Metabolisme ,Chemistry ,Succinate dehydrogenase ,Ischemia-reperfusion ,metabolismo::metabolismo energético::metabolismo::ciclo del ácido cítrico [FENÓMENOS Y PROCESOS] ,Remote ischemic conditioning ,Heart ,General Medicine ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Computer Science Applications ,Malonate ,myocardial infarction ,Other subheadings::Other subheadings::/administration & dosage [Other subheadings] ,sustancias macromoleculares::complejos multiproteicos::complejos multienzimáticos::succinato citocromo c oxidorreductasa::complejo II de transporte de electrones::succinato deshidrogenasa [COMPUESTOS QUÍMICOS Y DROGAS] ,QH301-705.5 ,Sodium ,Citric Acid Cycle ,chemistry.chemical_element ,Catalysis ,Great cardiac vein ,Article ,Inorganic Chemistry ,03 medical and health sciences ,Metabolism::Energy Metabolism::Metabolism::Citric Acid Cycle [PHENOMENA AND PROCESSES] ,medicine ,Animals ,Physical and Theoretical Chemistry ,Molecular Biology ,QD1-999 ,Macromolecular Substances::Multiprotein Complexes::Multienzyme Complexes::Succinate Cytochrome c Oxidoreductase::Electron Transport Complex II::Succinate Dehydrogenase [CHEMICALS AND DRUGS] ,Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores] ,Myocardium ,Organic Chemistry ,medicine.disease ,succinate dehydrogenase ,malonate ,Citric acid cycle ,Infart de miocardi ,030104 developmental biology ,Coronary Occlusion ,Inhibidors enzimàtics ,Coronary occlusion ,biology.protein ,Biomarkers - Abstract
Succinate dehydrogenase (SDH) inhibition with malonate during reperfusion reduced myocardial infarction in animals, whereas its endogenous substrate, succinate, is detected in plasma from STEMI patients. We investigated whether protection by SDH inhibition is additive to that of remote ischemic perconditioning (RIC) in pigs submitted to transient coronary artery occlusion, and whether protective maneuvers influence plasma levels of citric acid cycle metabolites. Forty pigs were submitted to 40 min coronary occlusion and reperfusion, and allocated to four groups (controls, sodium malonate 10 mmol/L, RIC, and malonate + RIC). Plasma was obtained from femoral and great cardiac veins and analyzed by LC-MS/MS. Malonate, RIC, and malonate + RIC reduced infarct size (24.67 ± 5.98, 25.29 ± 3.92 and 29.83 ± 4.62% vs. 46.47 ± 4.49% in controls, p <, 0.05), but no additive effects were detected. Enhanced concentrations of succinate, fumarate, malate and citrate were observed in controls during initial reperfusion in the great cardiac vein, and most were reduced by cardioprotective maneuvers. Concentrations of succinate, fumarate, and malate significantly correlated with infarct size. In conclusion, despite the combination of SDH inhibition during reperfusion and RIC did not result in additive protection, plasma concentrations of selected citric acid cycle metabolites are attenuated by protective maneuvers, correlate with irreversible injury, and might become a prognosis tool in STEMI patients.
- Published
- 2021
25. Choice of CTO scores to predict procedural success in clinical practice. A comparison of 4 different CTO PCI scores in a comprehensive national registry including expert and learning CTO operators
- Author
-
Javier Martín-Moreiras, Ignacio J. Amat-Santos, Juan Caballero Borrego, Jesús Jiménez-Mazuecos, Gema Miñana, Julio Núñez, Pablo Salinas, Sergio Rojas, José M. de la Torre Hernández, Guillermo Galeote, Manuel Fuentes, Eva Rumiz, Sandra Santos-Martínez, Fernando Lozano, Soledad Ojeda, José Antonio Fernández-Díaz, Javier Cuesta, Daniela Dubois, Javier Lacunza, Javier Goicolea, Javier Escaned, Alejandro Diego-Nieto, Alfonso Jurado, Sergio Rodríguez-Leiras, Manel Sabaté, Victoria Martin-Yuste, Francisco J Morales-Ponce, Juan Sanchis, Nieves Gonzalo, Miriam Jiménez-Fernández, Raúl Millán, Alejandro Gutiérrez, María M. López, Juan Rondan, Manuel Pan, Francisco Bosa Ojeda, Víctor H Moreno, Beatriz Vaquerizo, Fernando Rivero, J. Robles, Dae-Hyun Lee, Mohsen Mohandes, [Salinas,P, Gonzalo,N, Moreno,VH, Escaned,J] Cardiology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Fuentes,M] Servicio de Medicina Preventiva, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. [Santos-Martinez,S, Amat-Santos,IJ] Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Fernandez-Diaz,JA, Goicolea,J] Interventional Cardiology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain. [Bosa Ojeda,F] Servicio de Cardiología, H. Tenerife, Tenerife, Spain. [Caballero Borrego,J, Jiménez-Fernández,M] Servicio de Cardiología, HU. San Cecilio, Granada, Spain. [Cuesta,J, Rivero,F] Servicio de Cardiología, H. de la Princesa, Madrid, Spain. [de la Torre Hernández,JM, Lee,DH] Servicio de Cardiología, H. Valdecilla, Santander, Spain. [Diego-Nieto,A, Martin-Moreiras,J] Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca, IBSAL, CIBERCV, Salamanca, España. [Dubois,D, Millán,R, Vaquerizo,B] Servicio de Cardiología, H. del Mar, Barcelona, Spain. [Galeote,G, Jurado,A] Servicio de Cardiología, H. la Paz, Madrid, Spain. [Gutiérrez,A] Servicio de Cardiología, H. Jerez, Jerez, Spain. [Jiménez-Mazuecos,J] Servicio de Cardiología, H. Albacete, Albacete, Spain. [Jurado,A, Lozano,F] Servicio de Cardiología, H. Ciudad Real, Ciudad Real, Spain. [Lacunza,J] Servicio de Cardiología, H. de la Arrixaca, Murcia, Spain. [López,M] Servicio de Cardiología, H. León, León, Spain. [Martin-Yuste,V, Sabaté,M] CIBER CV, IDIBAPS, Instituto Cardiovascular, Servicio de Cardiología, H. Clinic Barcelona, Spain. [Miñana,G, Núñez,J, Sanchís,J] Servicio de Cardiología, H. Clínico de Valencia. Universidad de Valencia, CIBERCV, Valencia, Spain. [Mohandes,M, Rojas,S] Servicio de Cardiología, H. Joan XXIII, Tarragona, Spain. [Morales-Ponce,FJ] Servicio de Cardiología, H. Puerto Real, Puerto Real, Spain. [Ojeda,S, and Pan,M] Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), University of Córdoba, Córdoba, Spain. [Robles,J] Servicio de Cardiología, H. Burgos, Burgos, Spain. [Rodríguez-Leiras,S] Servicio de Cardiología, H. Virgen de la Macarena, Málaga, Spain. [Rondán,J] Servicio de Cardiología, H. Cabueñes, Gijón, Spain. [Rumiz,E] Servicio de Cardiología, H. General de Valencia, Valencia, Spain.
- Subjects
Male ,Calibración ,Cardiovascular Procedures ,Physiology ,medicine.medical_treatment ,Myocardial Infarction ,Social Sciences ,Vasos coronarios ,Cardiovascular Medicine ,Severity of Illness Index ,Percutaneous coronary intervention ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Calibration [Medical Subject Headings] ,Learning and Memory ,Medical Conditions ,Medicine and Health Sciences ,Psychology ,Registries ,Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,Coronary Artery Bypass Grafting ,Multidisciplinary ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Vascular Surgical Procedures::Endovascular Procedures::Percutaneous Coronary Intervention [Medical Subject Headings] ,Intervención coronaria percutánea ,Middle Aged ,Prognosis ,Interventional Cardiology ,Clinical Practice ,Treatment Outcome ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Surveys::Health Status Indicators::Patient Acuity::Severity of Illness Index [Medical Subject Headings] ,Cardiovascular Diseases ,Integrated discrimination improvement ,Area Under Curve ,Cohort ,Calibration ,Medicine ,Female ,Research Article ,Learning Curves ,medicine.medical_specialty ,Coronary Stenting ,Science ,Cardiology ,MEDLINE ,Check Tags::Male [Medical Subject Headings] ,Surgical and Invasive Medical Procedures ,Coronary artery ,Risk Assessment ,Total occlusion ,Calcification ,Percutaneous Coronary Intervention ,medicine ,Humans ,Learning ,Registros ,Aged ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings] ,business.industry ,Angioplasty ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment [Medical Subject Headings] ,Cognitive Psychology ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Area Under Curve [Medical Subject Headings] ,Biology and Life Sciences ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,Cardiovascular Disease Risk ,Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Coronary Disease::Coronary Occlusion [Medical Subject Headings] ,Coronary Occlusion ,Check Tags::Female [Medical Subject Headings] ,Stent Implantation ,Conventional PCI ,Physical therapy ,Cognitive Science ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,National registry ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings] ,Physiological Processes ,business ,Coronary Angioplasty ,Neuroscience - Abstract
Background We aimed to compare the performance of the recent CASTLE score to J-CTO, CL and PROGRESS CTO scores in a comprehensive database of percutaneous coronary intervention of chronic total occlusion procedures. Methods Scores were calculated using raw data from 1,342 chronic total occlusion procedures included in REBECO Registry that includes learning and expert operators. Calibration, discrimination and reclassification were evaluated and compared. Results Mean score values were: CASTLE 1.60±1.10, J-CTO 2.15±1.24, PROGRESS 1.68±0.94 and CL 2.52±1.52 points. The overall percutaneous coronary intervention success rate was 77.8%. Calibration was good for CASTLE and CL, but not for J-CTO or PROGRESS scores. Discrimination: the area under the curve (AUC) of CASTLE (0.633) was significantly higher than PROGRESS (0.557) and similar to J-CTO (0.628) and CL (0.652). Reclassification: CASTLE, as assessed by integrated discrimination improvement, was superior to PROGRESS (integrated discrimination improvement +0.036, p Conclusion Procedural percutaneous coronary intervention difficulty is not consistently depicted by available chronic total occlusion scores and is influenced by the characteristics of each chronic total occlusion cohort. In our study population, including expert and learning operators, the CASTLE score had slightly better overall performance along with CL score. However, we found only intermediate performance in the c-statistic predicting chronic total occlusion success among all scores.
- Published
- 2021
26. Malignant Arrhythmogenic Role Associated with RBM20: A Comprehensive Interpretation Focused on a Personalized Approach
- Author
-
Jordà, Paloma, Toro, Rocío, Diez, Carles, Salazar-Mendiguchía, Joel, Fernandez-Falgueras, Anna, Perez-Serra, Alexandra, Coll, Monica, Puigmulé, Marta, Arbelo, Elena, García-Álvarez, Ana, Sarquella-Brugada, Georgia, Cesar, Sergi, Tiron, Coloma, Iglesias, Anna, Brugada, Josep, Brugada, Ramon, Campuzano, Oscar, [Jordà,P, Arbelo,E, García-Álvarez,A, Brugada,J] Cardiology Department, Hospital Clinic, University of Barcelona-IDIBAPS, Barcelona, Spain. [Toro,R] Medicine Department, School of Medicine, University of Cadiz, Cadiz, Spain. [Toro,R] Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, Spain. [Diez,C, Salazar-Mendiguchía,J] Cardiovascular Diseases Research Group Bellvitge Biomedical Research Institute (IDIBELL) Hospitalet de Llobregat, Barcelona, Spain. [Diez,C] Advanced Heart Failure and Heart Transplant Unit Department of Cardiology Bellvitge University Hospital Hospitalet de Llobregat, Barcelona, Spain. [Fernandez-Falgueras,A, Perez-Serra,A, Coll,M, Puigmulé,M, Iglesias,A, Brugada,R, Campuzano,O] Cardiovascular Genetics Center, University of Girona-IDIBGI, Girona, Spain. [Perez-Serra,A, Brugada,J, Campuzano,O] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Sarquella-Brugada,G, Cesar,S, Campuzano,O] Pediatric Arrhythmias, Inherited Cardiac Diseases and Sudden Death Unit, Cardiology Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain. [Sarquella-Brugada,G, Campuzano,O] Medical Science Department, School of Medicine, University of Girona, Girona, Spain. [Tiron,C, Brugada,R] Cardiology Service, Hospital Josep Trueta, University of Girona, Girona, Spain., and This work was supported by Obra Social 'La Caixa Foundation' (LCF/PR/GN16/50290001 and LCF/PR/GN19/50320002), Fondo Investigacion Sanitaria (FIS PI16/01203 and FIS, PI17/01690) from Instituto Salud Carlos III (ISCIII), and 'Fundacio Privada Daniel Bravo Andreu'. CIBERCV is an initiative of the ISCIII, Spanish Ministry of Economy and Competitiveness.
- Subjects
RBM20 ,Phenomena and Processes::Genetic Phenomena::Phenotype [Medical Subject Headings] ,Anatomy::Musculoskeletal System::Muscles [Medical Subject Headings] ,Dilated cardiomyopathy ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Nucleoproteins::RNA-Binding Proteins [Medical Subject Headings] ,Supresión genética ,Genética ,Arritmias cardíacas ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Sudden cardiac death ,Cardiomiopatía dilatada ,Diseases::Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac [Medical Subject Headings] ,Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::RNA Processing, Post-Transcriptional::RNA Splicing [Medical Subject Headings] ,Muerte súbita cardíaca ,Diseases::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies [Medical Subject Headings] ,Genetics ,Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings] ,Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::RNA Processing, Post-Transcriptional::RNA Splicing::Alternative Splicing [Medical Subject Headings] ,Arrhythmia - Abstract
The RBM20 gene encodes the muscle-specific splicing factor RNA-binding motif 20, a regulator of heart-specific alternative splicing. Nearly 40 potentially deleterious variants in RBM20 have been reported in the last ten years, being found to be associated with highly arrhythmogenic events in familial dilated cardiomyopathy. Frequently, malignant arrhythmias can be a primary manifestation of disease. The early recognition of arrhythmic genotypes is crucial in avoiding lethal episodes, as it may have an impact on the adoption of personalized preventive measures. Our study performs a comprehensive update of data concerning rare variants in RBM20 that are associated with malignant arrhythmogenic phenotypes with a focus on personalized medicine. Yes
- Published
- 2021
27. Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV
- Author
-
Calvet-Mirabent, Marta, Sánchez-Cerrillo, Ildefonso, Martín-Cófreces, Noa, Martínez-Fleta, Pedro, de la Fuente, Hortensia, Tsukalov, Ilya, Delgado-Arevalo, Cristina, Calzada García, María Josefa, Santos Gil, Ignacio de los, Sanz Sanz, Jesús, García-Fraile, Lucio, Sánchez Madrid, Francisco, Alfranca González, Arantzazu, Muñoz Fernández, María Angeles, Buzón, Maria J., Martín-Gayo, Enrique, Institut Català de la Salut, [Calvet-Mirabent M, Sánchez-Cerrillo I] Immunology Unit from Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain. Universidad Autónoma de Madrid, Madrid, Spain. [Martín-Cófreces N] Immunology Unit from Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain. Universidad Autónoma de Madrid, Madrid, Spain. Centro de Investigación Biomédica en Red Cardiovascular, CIBERCV, Madrid, Spain. [Martínez-Fleta P] Immunology Unit from Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain. [de la Fuente H] Immunology Unit from Hospital Universitario de La Princesa and Instituto de Investigación Sanitaria Princesa, Madrid, Spain. Centro de Investigación Biomédica en Red Cardiovascular, CIBERCV, Madrid, Spain. [Tsukalov I] Universidad Autónoma de Madrid, Madrid, Spain. [Buzón MJ] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Ministerio de Ciencia y Competitividad (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Comunidad de Madrid (España), Gilead Sciences (Spain), Fundación La Caixa, Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación (España)
- Subjects
CD4-Positive T-Lymphocytes ,CD8 T cell + ,virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES] ,Medicina ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,HIV Infections ,CD8-Positive T-Lymphocytes ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,General Biochemistry, Genetics and Molecular Biology ,Humans ,Antiretrovirals - Ús terapèutic ,Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections [DISEASES] ,sistemas sanguíneo e inmunológico::sistema inmunológico::células presentadoras de antígenos::sistemas sanguíneo e inmunológico::sistema inmunológico::células dendríticas [ANATOMÍA] ,Immune exhaustion ,HIV ,acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos::antirretrovirales [COMPUESTOS QUÍMICOS Y DROGAS] ,Dendritic Cells ,General Medicine ,Hemic and Immune Systems::Immune System::Antigen-Presenting Cells::Hemic and Immune Systems::Immune System::Dendritic Cells [ANATOMY] ,Infeccions per VIH - Tractament ,Metabolism ,Anti-Retroviral Agents ,Cèl·lules dendrítiques ,HIV-1 ,Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents [CHEMICALS AND DRUGS] ,Immunotherapy ,Dendritic cell - Abstract
Background: Dysfunction of CD8+ T cells in people living with HIV-1 (PLWH) receiving anti-retroviral therapy (ART) has restricted the efficacy of dendritic cell (DC)-based immunotherapies against HIV-1. Heterogeneous immune exhaustion and metabolic states of CD8+ T cells might differentially associate with dysfunction. However, specific parameters associated to functional restoration of CD8+ T cells after DC treatment have not been investigated. Methods: We studied association of restoration of functional HIV-1-specific CD8+ T cell responses after stimulation with Gag-adjuvant-primed DC with ART duration, exhaustion, metabolic and memory cell subsets profiles. Findings: HIV-1-specific CD8+ T cell responses from a larger proportion of PLWH on long-term ART (more than 10 years; LT-ARTp) improved polyfunctionality and capacity to eliminate autologous p24+ infected CD4+ T cells in vitro. In contrast, functional improvement of CD8+ T cells from PLWH on short-term ART (less than a decade; ST-ARTp) after DC treatment was limited. This was associated with lower frequencies of central memory CD8+ T cells, increased co-expression of PD1 and TIGIT and reduced mitochondrial respiration and glycolysis induction upon TCR activation. In contrast, CD8+ T cells from LT-ARTp showed increased frequencies of TIM3+ PD1− cells and preserved induction of glycolysis. Treatment of dysfunctional CD8+ T cells from ST-ARTp with combined anti-PD1 and anti-TIGIT antibodies plus a glycolysis promoting drug restored their ability to eliminate infected CD4+ T cells. Interpretation: Together, our study identifies specific immunometabolic parameters for different PLWH subgroups potentially useful for future personalized DC-based HIV-1 vaccines. Funding: NIH (R21AI140930), MINECO/FEDER RETOS (RTI2018-097485-A-I00) and CIBERINF grants, NIH (R21AI140930), MINECO/FEDER RETOS (RTI2018-097485-A-I00) and CIBERINF grants
- Published
- 2022
- Full Text
- View/download PDF
28. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion
- Author
-
[Penela P, Mayor Jr F] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Inserte J, Rodriguez-Sinovas A, Garcia-Dorado D] CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Ramos P] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain and Hospital Universitari Vall d'Hebron
- Subjects
Cardiovascular Diseases::Heart Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Cardiovascular Diseases::Cardiovascular Diseases::Myocardial Reperfusion Injury [DISEASES] ,Proteïna quinasa CK2 ,Técnicas de Investigación::Modelos Animales::Técnicas de Investigación::Modelos Animales de Enfermedad [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,metabolism ,Reperfusió miocardíaca ,Models animals en la investigació ,Investigative Techniques::Models, Animal::Investigative Techniques::Disease Models, Animal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedades cardiovasculares::enfermedades cardiovasculares::daño por reperfusión miocárdica [ENFERMEDADES] ,metabolismo ,Amino Acids, Peptides, and Proteins::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::G-Protein-Coupled Receptor Kinases::beta-Adrenergic Receptor Kinases::G-Protein-Coupled Receptor Kinase 2 [CHEMICALS AND DRUGS] ,Aminoácidos, Péptidos y Proteínas::Péptidos::Péptidos y Proteínas de Señalización Intracelular::Quinasas de Receptores Acoplados a Proteína-G::Quinasas de Receptores Adrenérgicos beta::Aminoácidos, Péptidos y Proteínas::Quinasa 2 del Receptor Acoplado a Proteína-G [COMPUESTOS QUÍMICOS Y DROGAS] - Published
- 2021
29. Opposite effects of moderate and extreme Cx43 deficiency in conditional Cx43-deficient mice on angiotensin II-induced cardiac fibrosis
- Author
-
[Valls-Lacalle L, Negre-Pujol C, Valera-Cañellas A, Consegal M, Rodríguez-Sinovas A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Rodríguez C] Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Institut de Recerca del Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain. [Varona S] Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), Barcelona, Spain. Institut de Recerca del Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain and Hospital Universitari Vall d'Hebron
- Subjects
Eukaryota::Animals::Animal Population Groups::Animals, Genetically Modified::Mice, Transgenic::Mice, Knockout [ORGANISMS] ,Cardiovascular Diseases::Heart Diseases::Cardiomyopathies [DISEASES] ,enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías [ENFERMEDADES] ,Miocardi - Malalties ,aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::proteínas de transporte de membrana::conexinas::conexina 43 [COMPUESTOS QUÍMICOS Y DROGAS] ,Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Membrane Transport Proteins::Connexins::Connexin 43 [CHEMICALS AND DRUGS] ,Models animals en la investigació ,Eucariontes::Animales::Grupos de Población Animal::Animales Modificados Genéticamente::Ratones Transgénicos::Ratones Noqueados [ORGANISMOS] ,Connexines - Published
- 2021
30. Toll-Like Receptors in Acute Kidney Injury
- Author
-
Sandra Rayego-Mateos, Mercedes Vallejo-Mudarra, Isabel Cortegano, María Luisa Gaspar, Carmen Herencia-Bellido, Lucas Opazo-Ríos, Melania Guerrero-Hue, Cristina Vázquez-Carballo, José Luis Morgado-Pascual, Cristina García-Caballero, Juan Antonio Moreno, Belén de Andrés, Jesús Egido, [Vázquez-Carballo,C, Rayego-Mateos,S, Opazo-Ríos,L, Herencia-Bellido,C, Egido,J] Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain. [Guerrero-Hue,M, García-Caballero,C, Morgado-Pascual,JL, Vallejo-Mudarra,M, Moreno,JA] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, Spain. [Opazo-Ríos,L, Egido,J] Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. [Cortegano,I, Gaspar,ML, de Andrés,B] Immunobiology Department, Carlos III Health Institute, Majadahonda (Madrid), Spain. [Moreno,JA] Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain. [Moreno,JA] Department of Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI20/00375, PI20/00487), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-099114-B-100, RTI2018-098788-B-100, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The 'PFIS' and 'Sara Borrell' training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C. No other relevant affiliations or financial involvement exist with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties., Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Sociedad Española de Cardiología, Sociedad Española de Nefrología, Sociedad Española de Arteriosclerosis, University of Córdoba (España), UAM. Departamento de Farmacología, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), and Universidad de Córdoba
- Subjects
0301 basic medicine ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors::Toll-Like Receptor 4 [Medical Subject Headings] ,Anatomy::Urogenital System::Urinary Tract::Kidney [Medical Subject Headings] ,Nefrología y urología ,medicine.medical_treatment ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [Medical Subject Headings] ,Review ,Bioinformatics ,urologic and male genital diseases ,Kidney ,drugs ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Lesión renal aguda ,lcsh:Chemistry ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Risk Factors ,Chronic kidney disease ,Epidemiology ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,Insuficiencia renal crónica ,Receptor ,lcsh:QH301-705.5 ,Spectroscopy ,Diseases::Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic [Medical Subject Headings] ,Toll-Like Receptors ,Acute kidney injury ,Drugs ,General Medicine ,Acute Kidney Injury ,female genital diseases and pregnancy complications ,Computer Science Applications ,Renal Replacement Therapy ,Terapia ,030220 oncology & carcinogenesis ,Disease Progression ,Medicamentos ,Persons::Persons::Patients::Survivors [Medical Subject Headings] ,medicine.symptom ,Factores de riesgo ,medicine.medical_specialty ,Medicina ,Receptores toll-like ,Inflammation ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents [Medical Subject Headings] ,Catalysis ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Renal Replacement Therapy [Medical Subject Headings] ,Inorganic Chemistry ,03 medical and health sciences ,Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Internationality::International Cooperation::Developing Countries [Medical Subject Headings] ,medicine ,Animals ,Humans ,Renal replacement therapy ,Physical and Theoretical Chemistry ,Renal Insufficiency, Chronic ,Molecular Biology ,Pathological ,Diseases::Cardiovascular Diseases [Medical Subject Headings] ,therapy ,Inflamación ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings] ,business.industry ,urogenital system ,Organic Chemistry ,and therapy ,medicine.disease ,Toll-like receptors ,Toll-Like Receptor 4 ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Risk factors ,inflammation ,TLR4 ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors [Medical Subject Headings] ,Therapy ,business ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings] ,Kidney disease - Abstract
Acute kidney injury (AKI) is an important health problem, affecting 13.3 million individuals/year. It is associated with increased mortality, mainly in low- and middle-income countries, where renal replacement therapy is limited. Moreover, survivors show adverse long-term outcomes, including increased risk of developing recurrent AKI bouts, cardiovascular events, and chronic kidney disease. However, there are no specific treatments to decrease the adverse consequences of AKI. Epidemiological and preclinical studies show the pathological role of inflammation in AKI, not only at the acute phase but also in the progression to chronic kidney disease. Toll-like receptors (TLRs) are key regulators of the inflammatory response and have been associated to many cellular processes activated during AKI. For that reason, a number of anti-inflammatory agents targeting TLRs have been analyzed in preclinical studies to decrease renal damage during AKI. In this review, we updated recent knowledge about the role of TLRs, mainly TLR4, in the initiation and development of AKI as well as novel compounds targeting these molecules to diminish kidney injury associated to this pathological condition, The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI20/00375, PI20/00487), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-099114-B-100, RTI2018-098788-B-100, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C.
- Published
- 2021
31. Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Long-Term Survival
- Author
-
Bermejo, Javier, González-Mansilla, Ana, Mombiela, Teresa, Fernández, Ana I., Martínez-Legazpi, Pablo, Yotti, Raquel, García-Orta, Rocío, Sánchez-Fernández, Pedro L., Castaño, Mario, Segovia-Cubero, Javier, Escribano-Subias, Pilar, San Román, J.Alberto, Borràs Pino, Xavier, Alonso-Gómez, Ángel María, Botas, Javier, Crespo-Leiro, Maria Generosa, Velasco, Sonia, Bayés-Genís, Antoni, López, Amador, Muñoz-Aguilera, Roberto, Jiménez-Navarro, Manuel, González-Juanatey, José R., Evangelista, Arturo, Elízaga, Jaime, Martín-Moreiras, Javier, González-Santos, José M., Moreno-Escobar, Eduardo, Fernández Avilés, F., García-Robles, José A., Pérez-David, Esther, Pérez Del Villar, Candelas, Sanz, Ricardo, Gutierrez-Ibanes, Enrique, Vázquez, María E., Mur, Ana, Benito, Yolanda, Barrio, Alicia, Vázquez, Alexandra, Uribe, Inés, González, Mercedes, Arribas, Antonio, Clemente Lorenzo, M. Milagros, Nieto, Alejandro Diego, Pérez De Prado, Armando, Alonso, David, Gómez-Bueno, Manuel, Sayago Silva, Inés, Cavero, Miguel Ángel, Domínguez, Laura, Tello De Meneses, Rocío, Ruíz Cano, María José, Jiménez López-Guarch, Carmen, Mota, Pedro, Amorós Galitó, Carmen, Belló Mora, M. Concepción, Mesa Rubio, Dolores, Campuzano, Raquel, Marzoa, Raquel, Cuenca, José, Muñoz, Roberto, Suberviola, Verónica, Beltrán Herrera, Cristina, Mora, Laura, Sarrión, M. Mar, Vaqueriza, David, Ferrer, Elena, Cid-Álvarez, Belén, Martínez Monzonís, Amparo, Arizón De Prado, José M., Santisteban, Marta, García-Dorado, David, De Teresa, Eduardo, Carrasco-Chinchilla, Fernando, Alonso, Joaquín, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), European Regional Development Fund (ERDF/FEDER), Centro de Investigación Biomedica en Red - CIBER, Institut Català de la Salut, [Bermejo J, González-Mansilla A, Mombiela T, Fernández AI, Martínez-Legazpi P] Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, and CIBERCV Madrid Spain. [Yotti R] Instituto de Salud Carlos III Madrid Spain. [Evangelista A] Vall d'Hebron Hospital Universitari, Barcelona, Spain. CIBERCV Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,Heart Valve Diseases ,Hemodynamics ,Long Term Adverse Effects ,heart failure ,030204 cardiovascular system & hematology ,Valvular heart diseas ,0302 clinical medicine ,Postoperative Complications ,Risk Factors ,Hipertensió pulmonar - Factors de risc ,pulmonary hypertension ,030212 general & internal medicine ,Original Research ,Heart Valve Prosthesis Implantation ,valvular heart disease ,Organ Size ,Middle Aged ,Heart Valves ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,enfermedades respiratorias::enfermedades pulmonares::hipertensión pulmonar [ENFERMEDADES] ,Hypertension, Pulmonary ,Heart failure ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades de las válvulas cardíacas [ENFERMEDADES] ,técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Sildenafil Citrate ,Pulmonary hypertension ,03 medical and health sciences ,Respiratory Tract Diseases::Lung Diseases::Hypertension, Pulmonary [DISEASES] ,Double-Blind Method ,Internal medicine ,Long term survival ,medicine ,Diabetes Mellitus ,Humans ,Pulmonary Wedge Pressure ,business.industry ,Persistent pulmonary hypertension ,Cor - Vàlvules - Malalties ,Phosphodiesterase 5 Inhibitors ,medicine.disease ,Valvular heart disease ,Valvular Heart Disease ,Cardiovascular Diseases::Heart Diseases::Heart Valve Diseases [DISEASES] ,Vascular Resistance ,Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,business - Abstract
Background The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with this condition. Methods and Results We analyzed long‐term follow‐up data of 222 patients with pulmonary hypertension and valvular heart disease successfully corrected at least 1 year before enrollment who had undergone comprehensive hemodynamic and imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median (interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated postcapillary pulmonary hypertension. After a median follow‐up of 4.5 years, 91 deaths accounted for 4.21 higher‐than‐expected mortality in the age‐matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or approximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six‐month changes in the composite clinical score and in the 6‐minute walk test distance were related to survival. Conclusions Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally associated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have important implications for individualizing valve correction procedures. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00862043.
- Published
- 2021
32. The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe
- Author
-
Ivan Milinković, Antoni Bayes-Genis, Henrike Arfsten, Tiny Jaarsma, Patrick Rossignol, Arantxa González, Pardeep S. Jhund, James L. Januzzi, Rudolf A. de Boer, A. Mark Richards, Andrew J.S. Coats, Michele Emdin, Giuseppe M.C. Rosano, Christian Mueller, Petar M. Seferovic, Julio Núñez, BOZEC, Erwan, Heart Institute, Hospital Universitari Germans Trias i Pujol, CIBERCV, Instituto de Salud Carlos III, Massachusetts General Hospital [Boston], Baim Institute for Clinical Research Boston MA, Harvard Medical School [Boston] (HMS), Cardiovascular Research Institute, National University Heart Centre, University of Otago [Dunedin, Nouvelle-Zélande], Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, University Medical Center Groningen [Groningen] (UMCG), Fondazione Toscana Gabriele Monasterio, Institute of Life Sciences, Scuola Superiore Sant'Anna, Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain, CIBERCV, Carlos III Institute of Health, Division of Nursing Sciences and Reproductive Health, Department of Health, Medicine and Caring Sciences, Linköping University, British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), University of Glasgow-NHS Greater Glasgow and Clyde, University Hospital Basel [Basel], University of Basel (Unibas), Biomedical Research Institute [Valencia, Spain] (INCLIVA ), Universitat de València (UV), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), University of Belgrade [Belgrade], niversity and IRCCS San Raffaele, University of Warwick [Coventry], Monash University [Melbourne], Serbian Academy of Sciences and Arts (SASA), and Cardiovascular Centre (CVC)
- Subjects
medicine.medical_specialty ,NT-PROBNP ,MEDLINE ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Natriuretic Peptide, Brain ,medicine ,MANAGEMENT ,Humans ,Cardiac and Cardiovascular Systems ,030212 general & internal medicine ,Natriuretic Peptides ,Intensive care medicine ,DYSPNEA ,Heart Failure ,Kardiologi ,business.industry ,Emergency department ,ASSOCIATION ,medicine.disease ,Peptide Fragments ,EMERGENCY-DEPARTMENT ,3. Good health ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Europe ,Action (philosophy) ,Heart failure ,Peptides ,Cardiology and Cardiovascular Medicine ,business ,Atrial Natriuretic Factor ,Biomarkers - Abstract
n/a Funding Agencies|Applied Therapeutics; Innolife; Novartis PharmaceuticalsNovartis; Abbott DiagnosticsAbbott Laboratories; AstraZenecaAstraZeneca; AbbottAbbott Laboratories; Boehringer IngelheimBoehringer Ingelheim; Cardior Pharmaceuticals Gmbh; Ionis Pharmaceuticals, Inc.; Novo NordiskNovo Nordisk; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Swiss Heart Foundation; KTI; European UnionEuropean Commission; University of Basel; University Hospital Basel; Beckman Coulter; BRAHMS; Idorsia; NovartisNovartis; Ortho Clinical Diagnostics; Quidel; SiemensSiemens AG; Singulex; Sphingotec; CardioRenal
- Published
- 2021
- Full Text
- View/download PDF
33. Improving Uncertainty Estimation With Semi-Supervised Deep Learning for COVID-19 Detection Using Chest X-Ray Images
- Author
-
Simon Colreavy-Donnelly, Saul Calderon-Ramirez, Shengxiang Yang, Ezequiel López-Rubio, David Elizondo, Manuel F. Jiménez-Navarro, Armaghan Moemeni, Luis Oala, Jorge Rodriguez-Capitan, Miguel A. Molina-Cabello, [Calderon-Ramirez, Saul] De Montfort Univ, Sch Comp Sci & Informat, Leicester LE1 9BH, Leics, England, [Yang, Shengxiang] De Montfort Univ, Sch Comp Sci & Informat, Leicester LE1 9BH, Leics, England, [Colreavy-Donnelly, Simon] De Montfort Univ, Sch Comp Sci & Informat, Leicester LE1 9BH, Leics, England, [Elizondo, David A.] De Montfort Univ, Sch Comp Sci & Informat, Leicester LE1 9BH, Leics, England, [Calderon-Ramirez, Saul] Inst Tecnol Costa Rica, Cartago 30101, Costa Rica, [Moemeni, Armaghan] Univ Nottingham, Sch Comp Sci, Nottingham NG8 1BB, England, [Oala, Luis] Fraunhofer Heinrich Hertz Inst, XAI Grp, Artificial Intelligence Dept, D-10587 Berlin, Germany, [Rodriguez-Capitan, Jorge] Hosp Univ Virgen Victoria, CIBERCV, Malaga 29010, Spain, [Jimenez-Navarro, Manuel] Hosp Univ Virgen Victoria, CIBERCV, Malaga 29010, Spain, [Lopez-Rubio, Ezequiel] Univ Malaga, Dept Comp Languages & Comp Sci, Malaga 29071, Spain, [Molina-Cabello, Miguel A.] Univ Malaga, Dept Comp Languages & Comp Sci, Malaga 29071, Spain, [Lopez-Rubio, Ezequiel] Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain, [Molina-Cabello, Miguel A.] Inst Invest Biomed Malaga IBIMA, Malaga 29010, Spain, Universidad de Malaga, Instituto de Investigacion Biomedica de Malaga (IBIMA), and Publica
- Subjects
General Computer Science ,Computer science ,Measurement uncertainty ,Monte Carlo method ,Uncertainty estimation ,010501 environmental sciences ,Machine learning ,computer.software_genre ,01 natural sciences ,chest x-ray ,Imaging ,03 medical and health sciences ,General Materials Science ,Uncertainty quantification ,Reliability (statistics) ,Dropout (neural networks) ,030304 developmental biology ,0105 earth and related environmental sciences ,0303 health sciences ,Measurement ,computer aided diagnosis ,business.industry ,Deep learning ,X-ray imaging ,General Engineering ,Uncertainty ,COVID-19 ,TK1-9971 ,Coronavirus ,Softmax function ,Metric (mathematics) ,semi-supervised deep learning ,MixMatch ,Computational and Artificial Intelligence ,Artificial intelligence ,Electrical engineering. Electronics. Nuclear engineering ,business ,Covid-19 ,computer ,Estimation - Abstract
In this work we implement a COVID-19 infection detection system based on chest X-ray images with uncertainty estimation. Uncertainty estimation is vital for safe usage of computer aided diagnosis tools in medical applications. Model estimations with high uncertainty should be carefully analyzed by a trained radiologist. We aim to improve uncertainty estimations using unlabelled data through the MixMatch semi-supervised framework. We test popular uncertainty estimation approaches, comprising Softmax scores, Monte-Carlo dropout and deterministic uncertainty quantification. To compare the reliability of the uncertainty estimates, we propose the usage of the Jensen-Shannon distance between the uncertainty distributions of correct and incorrect estimations. This metric is statistically relevant, unlike most previously used metrics, which often ignore the distribution of the uncertainty estimations. Our test results show a significant improvement in uncertainty estimates when using unlabelled data. The best results are obtained with the use of the Monte Carlo dropout method.
- Published
- 2021
34. Local administration of porcine immunomodulatory, chemotactic and angiogenic extracellular vesicles using engineered cardiac scaffolds for myocardial infarction
- Author
-
Francesc E. Borràs, S. Roura, Adriana Cserkóová, Paloma Gastelurrutia, Miriam Morón-Font, Anna Rosell, Carolina Gálvez-Montón, Alexandra Calle, Marta Monguió-Tortajada, Anna Morancho, Antoni Bayes-Genis, Marta Clos-Sansalvador, Miguel Ángel Ramírez, Cristina Prat-Vidal, Institut Català de la Salut, [Monguió-Tortajada M] ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain. REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERCV, Instituto de Salud Carlos III, Madrid, Spain. [Prat-Vidal C, Gastelurrutia P] ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain. CIBERCV, Instituto de Salud Carlos III, Madrid, Spain. Institut d’Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain. [Moron-Font M] REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain. [Clos-Sansalvador M] REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Calle A] Departamento de Reproducción Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain. [Morancho A, Rosell A] Laboratori d'Investigació Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
QH301-705.5 ,Angiogenesis ,0206 medical engineering ,Biomedical Engineering ,Adipose tissue ,Inflammation ,02 engineering and technology ,Cardiac tissue engineering ,Exosomes ,Article ,Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Myocardial Infarction [DISEASES] ,Biomaterials ,Otros calificadores::Otros calificadores::Otros calificadores::/trasplante [Otros calificadores] ,In vivo ,Cells::Cellular Structures::Extracellular Space::Extracellular Vesicles [ANATOMY] ,medicine ,Macrophage ,Miocardi - Regeneració ,Tissue engineering ,Infart de miocardi - Tractament ,Biology (General) ,Materials of engineering and construction. Mechanics of materials ,Otros calificadores::/terapia [Otros calificadores] ,Migration ,Other subheadings::Other subheadings::Other subheadings::/transplantation [Other subheadings] ,Mesenchymal stem/stromal cells ,Chemistry ,células::estructuras celulares::espacio extracelular::vesículas extracelulares [ANATOMÍA] ,Mesenchymal stem cell ,Infiltration ,Other subheadings::/therapy [Other subheadings] ,021001 nanoscience & nanotechnology ,020601 biomedical engineering ,enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::infarto de miocardio [ENFERMEDADES] ,Microvesicles ,Cell biology ,Infart de miocardi ,Myocardial infarction ,Enginyeria de teixits ,TA401-492 ,Tumor necrosis factor alpha ,medicine.symptom ,0210 nano-technology ,Biotechnology - Abstract
The administration of extracellular vesicles (EV) from mesenchymal stromal cells (MSC) is a promising cell-free nanotherapy for tissue repair after myocardial infarction (MI). However, the optimal EV delivery strategy remains undetermined. Here, we designed a novel MSC-EV delivery, using 3D scaffolds engineered from decellularised cardiac tissue as a cell-free product for cardiac repair. EV from porcine cardiac adipose tissue-derived MSC (cATMSC) were purified by size exclusion chromatography (SEC), functionally analysed and loaded to scaffolds. cATMSC-EV markedly reduced polyclonal proliferation and pro-inflammatory cytokines production (IFNγ, TNFα, IL12p40) of allogeneic PBMC. Moreover, cATMSC-EV recruited outgrowth endothelial cells (OEC) and allogeneic MSC, and promoted angiogenesis. Fluorescently labelled cATMSC-EV were mixed with peptide hydrogel, and were successfully retained in decellularised scaffolds. Then, cATMSC-EV-embedded pericardial scaffolds were administered in vivo over the ischemic myocardium in a pig model of MI. Six days from implantation, the engineered scaffold efficiently integrated into the post-infarcted myocardium. cATMSC-EV were detected within the construct and MI core, and promoted an increase in vascular density and reduction in macrophage and T cell infiltration within the damaged myocardium. The confined administration of multifunctional MSC-EV within an engineered pericardial scaffold ensures local EV dosage and release, and generates a vascularised bioactive niche for cell recruitment, engraftment and modulation of short-term post-ischemic inflammation., Graphical abstract Image 1, Highlights • A bioactive engineered scaffold can locally deliver EV to the infarcted myocardium. • Porcine cATMSC-EV promote endothelial cell recruitment and in vivo vascularization. • Porcine cATMSC-EV reduce inflammation, and macrophage and T cell infiltration.
- Published
- 2021
35. Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer
- Author
-
Sergio Rius-Pérez, Carmen Choya-Foces, Jordi Muntané, María A. Rodríguez-Hernández, Antonio Miranda-Vizuete, C. Alicia Padilla, Raúl González, Antonio Martínez-Ruiz, Juan Sastre, María Negrete, Patricia de la Cruz-Ojeda, Kalina Ranguelova, Anne-Odile Hueber, José Antonio Bárcena, Aurélie Rossin, [González,R, Rodríguez-Hernández,MA, Negrete,M, de la Cruz-Ojeda,P, Miranda-Vizuete,A, Muntané,J] Institute of Biomedicine of Seville (IBiS), Hospital University 'Virgen Del Rocío'/CSIC/University of Seville, Seville, Spain. [Ranguelova,K] Bruker BioSpin Corporation, Billerica, MA, USA. [Rossin,A, Hueber,AO] Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France. [Choya-Foces,C, Martínez-Ruiz,A] Research Unit, Hospital University 'Santa Cristina', Health Research Institute 'La Princesa' (IIS-IP), Madrid, Spain. [Choya-Foces,C, Martínez-Ruiz,A] Biomedical Research Network Center for Cardiovascular Diseases (CIBERCV), Madrid, Spain. [Rius-Pérez,S, Sastre,J] Department of Physiology, Faculty of Pharmacy, University of Valencia. Burjassot, Valencia, Spain. [Bárcena,JA, Padilla,CA] Department of Biochemistry and Molecular Biology, University of Cordoba, Cordoba, Spain. [Bárcena,JA, Padilla,CA] Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain. [Muntané,J] Department of General Surgery, Hospital University 'Virgen del Rocío'/IBiS/CSIC/University of Seville, Seville, Spain. [González,R, Muntané,J] Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd), Madrid, Spain., This study was funded by Institute of Health Carlos III (ISCIII) (PI13/00021, PI15/00107, PI16/00090 and PI19/01266), Spanish Ministry of Economy and Competitiveness (SAF2015-71208-R, BFU2016-8006-P, PGC2018-094276-B-I00 and RED2018-102576-T), Andalusian Ministry of Economy, Innovation, Science and Employment (BIO-216 and CTS-6264) and Andalusian Ministry of Equality, Health and Social Policies (PI-00025-2013 and PI-0198-2016). P de la C–O was supported by FPU predoctoral fellowship (FPU17/00026) from Ministry of Education, Culture and Sports. We thank the Biomedical Research Network Center for Cardiovascular Diseases (CIBERCV), and the Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd) founded by the ISCIII and co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF for their financial support., Institute of Biomedicine of Seville (IBIS), Bruker Biospin Corporation, Billerica, Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Santa Cristina University Hospital, University of Valencia, Valencia, University of Córdoba [Córdoba], Instituto de Biomedicina de Sevilla [Sevilla, Spain] (IBIS/HUVR), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Servicio de Immunologia, Hospital Universitario de la Princesa-Instituto de Investigacion Sanitaria Princesa, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Ministerio de Economía y Competitividad (España), Junta de Andalucía, Ministerio de Educación, Cultura y Deporte (España), Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (España), Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España), and European Commission
- Subjects
0301 basic medicine ,Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor [Medical Subject Headings] ,Factor 2 relacionado con NF-E2 ,Regulación hacia abajo ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Thioredoxins [Medical Subject Headings] ,Apoptosis ,Biochemistry ,Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Nitrosation [Medical Subject Headings] ,Targeted therapy ,Neoplasias hepáticas ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Mice ,0302 clinical medicine ,Thioredoxins ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,lcsh:QH301-705.5 ,Cell proliferation ,lcsh:R5-920 ,GSNOR ,Chemistry ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings] ,Liver Neoplasms ,Sorafenib ,Fas receptor ,3. Good health ,Hepatocellular carcinoma ,CD95 ,Liver cancer ,lcsh:Medicine (General) ,NOS3 ,Carcinoma hepatocelular ,Research Paper ,medicine.drug ,Hepatocarcinoma ,Proliferación celular ,Carcinoma, Hepatocellular ,Nitrosation ,Down-Regulation ,Mice, Nude ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Antineoplastic Agents ,Nrf2 ,03 medical and health sciences ,Downregulation and upregulation ,Cell Line, Tumor ,medicine ,Animals ,Humans ,S-Nitrosoglutatión ,Tiorredoxinas ,Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Growth Processes::Cell Proliferation [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice [Medical Subject Headings] ,Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular [Medical Subject Headings] ,Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Down-Regulation [Medical Subject Headings] ,Cell growth ,Phenylurea Compounds ,Organic Chemistry ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings] ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Mice::Mice, Mutant Strains::Mice, Nude [Medical Subject Headings] ,medicine.disease ,digestive system diseases ,030104 developmental biology ,lcsh:Biology (General) ,Downregulation ,Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Aromatic::Benzene Derivatives::Phenylurea Compounds [Medical Subject Headings] ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Cancer research ,Óxido nítrico sintasa de tipo III ,030217 neurology & neurosurgery - Abstract
Hepatocellular carcinoma (HCC) represents 80% of the primary hepatic neoplasms. It is the sixth most frequent neoplasm, the fourth cause of cancer-related death, and 7% of registered malignancies. Sorafenib is the first line molecular targeted therapy for patients in advanced stage of HCC. The present study shows that Sorafenib exerts free radical scavenging properties associated with the downregulation of nuclear factor E2-related factor 2 (Nrf2)-regulated thioredoxin 1 (Trx1) expression in liver cancer cells. The experimental downregulation and/or overexpression strategies showed that Trx1 induced activation of nitric oxide synthase (NOS) type 3 (NOS3) and S-nitrosation (SNO) of CD95 receptor leading to an increase of caspase-8 activity and cell proliferation, as well as reduction of caspase-3 activity in liver cancer cells. In addition, Sorafenib transiently increased mRNA expression and activity of S-nitrosoglutathione reductase (GSNOR) in HepG2 cells. Different experimental models of hepatocarcinogenesis based on the subcutaneous implantation of HepG2 cells in nude mice, as well as the induction of HCC by diethylnitrosamine (DEN) confirmed the relevance of Trx1 downregulation during the proapoptotic and antiproliferative properties induced by Sorafenib. In conclusion, the induction of apoptosis and antiproliferative properties by Sorafenib were related to Trx1 downregulation that appeared to play a relevant role on SNO of NOS3 and CD95 in HepG2 cells. The transient increase of GSNOR might also participate in the deactivation of CD95-dependent proliferative signaling in liver cancer cells., Graphical abstract Graphical Abstract. Sorafenib reduced ROS/RNS cytoplasmic concentrations which were associated with decreased Nrf2 nuclear translocation, Trx1 expression/activity, and SNO–NOS3 expression and NO intracellular generation in HepG2. The reduction of SNO–NOS3 expression and NO generation might also be influenced by the induction of transient GSNOR expression/activity and reduced NOS3 expression by Sorafenib. The diminution of SNO-CD95 expression by Sorafenib involved reduction of caspase-8 activity and cell proliferation, and increased downstream caspase-3 activity in liver cancer cells.Image 1, Highlights • Sorafenib induces mitochondrial ROS generation, but also acts as nucleophilic scavenger. • Sorafenib reduces Nrf2-depenent Trx1 expression, and SNO–NOS3 and SNO-CD95 ratios. • Sorafenib-related antitumoral in vivo activity involves diminution of Trx1 and SNO-CD95.
- Published
- 2020
- Full Text
- View/download PDF
36. Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
- Author
-
de la Fuente-Alonso, Andrea, Toral, Marta, Alfayate, Alvaro, Ruiz-Rodríguez, María Jesús, Bonzon-Kulichenko, Elena, Teixido-Tura, Gisela, Martínez-Martínez, Sara, Méndez-Olivares, María José, López-Maderuelo, Dolores, González-Valdés, Ileana, Garcia-Izquierdo, Eusebio, Mingo, Susana, Martín, Carlos E., Muiño-Mosquera, Laura, De Backer, Julie, Nistal, J. Francisco, Forteza, Alberto, Evangelista Masip, Arturo, Vázquez, Jesús, Campanero, Miguel R., Redondo, Juan Miguel, Universidad Autònoma de Barcelona, La Caixa, Ministerio de Ciencia e Innovación (España), Ministerio de Economía y Competitividad (España), Comunidad de Madrid, Institut Català de la Salut, [de la Fuente-Alonso A, Toral M, Ruiz-Rodríguez MJ] Gene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Alfayate A] Gene regulation in cardiovascular remodeling and inflammation group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Cardiovascular Proteomics Laboratoy, CNIC, Madrid, Spain. [Bonzón-Kulichenko E] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Cardiovascular Proteomics Laboratoy, CNIC, Madrid, Spain. [Teixido-Tura G, Evangelista A] Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Marfan syndrome ,Male ,CYCLIC-GMP ,Cardiopatia congènita ,PROTEIN-KINASES ,Fibrillin-1 ,General Physics and Astronomy ,030204 cardiovascular system & hematology ,Aortic diseases ,Cardiovascular Diseases::Vascular Diseases::Aneurysm::Aortic Aneurysm::Aortic Aneurysm, Thoracic [DISEASES] ,Muscle, Smooth, Vascular ,Marfan Syndrome ,chemistry.chemical_compound ,Aortic aneurysm ,Mice ,0302 clinical medicine ,enfermedades cardiovasculares::enfermedades vasculares::aneurisma::aneurisma de la aorta::aneurisma de la aorta torácica [ENFERMEDADES] ,Soluble Guanylyl Cyclase ,Medicine and Health Sciences ,Myocyte ,Otros calificadores::Otros calificadores::/antagonistas & inhibidores [Otros calificadores] ,skin and connective tissue diseases ,Cyclic GMP ,Aorta ,Cyclic GMP-Dependent Protein Kinase Type I ,Ultrasonography ,Multidisciplinary ,PLASMA ,integumentary system ,Gene Knockdown Techniques ,Female ,Aneurismes aòrtics ,musculoskeletal diseases ,medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,Other subheadings::Other subheadings::/antagonists & inhibitors [Other subheadings] ,Science ,ROOT DILATION ,Myocytes, Smooth Muscle ,Primary Cell Culture ,Carbazoles ,PEPTIDE IDENTIFICATION ,Genetics and Molecular Biology ,S-NITROSYLATION ,macromolecular substances ,enfermedades cardiovasculares::enfermedades cardiovasculares::enfermedades cardíacas::cardiopatías congénitas::síndrome de Marfan [ENFERMEDADES] ,Nitric Oxide ,Thoracic aortic aneurysm ,General Biochemistry, Genetics and Molecular Biology ,Nitric oxide ,MECHANISMS ,03 medical and health sciences ,Internal medicine ,medicine ,aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intracelular::guanilato ciclasa::aminoácidos, péptidos y proteínas::guanilil ciclasa soluble [COMPUESTOS QUÍMICOS Y DROGAS] ,Animals ,Humans ,Nitric Oxide Donors ,ANEURYSMS ,cardiovascular diseases ,Protein kinase A ,BETA-BLOCKER THERAPY ,NITRIC-OXIDE ,Aortic Aneurysm, Thoracic ,business.industry ,S-Nitrosylation ,General Chemistry ,medicine.disease ,Actin cytoskeleton ,Aneurysm ,Amino Acids, Peptides, and Proteins::Peptides::Intracellular Signaling Peptides and Proteins::Guanylate Cyclase::Amino Acids, Peptides, and Proteins::Soluble Guanylyl Cyclase [CHEMICALS AND DRUGS] ,Disease Models, Animal ,030104 developmental biology ,Endocrinology ,chemistry ,General Biochemistry ,Mutation ,business ,Cardiovascular Diseases::Cardiovascular Diseases::Heart Diseases::Heart Defects, Congenital::Marfan Syndrome [DISEASES] ,Biomarkers ,Inhibidors enzimàtics - Ús terapèutic - Abstract
Thoracic aortic aneurysm, as occurs in Marfan syndrome, is generally asymptomatic until dissection or rupture, requiring surgical intervention as the only available treatment. Here, we show that nitric oxide (NO) signaling dysregulates actin cytoskeleton dynamics in Marfan Syndrome smooth muscle cells and that NO-donors induce Marfan-like aortopathy in wild-type mice, indicating that a marked increase in NO suffices to induce aortopathy. Levels of nitrated proteins are higher in plasma from Marfan patients and mice and in aortic tissue from Marfan mice than in control samples, indicating elevated circulating and tissue NO. Soluble guanylate cyclase and cGMP-dependent protein kinase are both activated in Marfan patients and mice and in wild-type mice treated with NO-donors, as shown by increased plasma cGMP and pVASP-S239 staining in aortic tissue. Marfan aortopathy in mice is reverted by pharmacological inhibition of soluble guanylate cyclase and cGMP-dependent protein kinase and lentiviral-mediated Prkg1 silencing. These findings identify potential biomarkers for monitoring Marfan Syndrome in patients and urge evaluation of cGMP-dependent protein kinase and soluble guanylate cyclase as therapeutic targets., “La Caixa” Banking Foundation under project codes HR18-00068 (to M.R.C. and J.M.R.) and HR17-00247 (to J.V.); Spanish Ministerio de Ciencia e Innovación grants RTI2018-099246-B-I00 (MICIU/AEI/FEDER, UE) and SAF2015-636333R (MINECO/FEDER, UE) to J.M.R., SAF2017-88881R (MINECO/AEI/FEDER, UE) to M.R.C., and BIO2015-67580-P and PGC2018-097019-B-I00 to J.V.; the Comunidad de Madrid
- Published
- 2020
37. Planning the Follow-Up of Patients with Stable Chronic Coronary Artery Disease
- Author
-
Santiago Aguadé-Bruix, Guillermo Romero-Farina, Institut Català de la Salut, [Romero-Farina G] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aguadé-Bruix S] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBERCV, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Medicine (General) ,medicine.medical_specialty ,Cross-sectional study ,Clinical Biochemistry ,planning the follow-up ,Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Review ,Disease ,cross-sectional analysis ,Coronary artery disease ,R5-920 ,Clinical history ,Economic cost ,Health care ,medicine ,Intensive care medicine ,Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings] ,enfermedades cardiovasculares [ENFERMEDADES] ,Cause of death ,Cardiovascular Diseases [DISEASES] ,Imatgeria per al diagnòstic - Tècniques digitals ,business.industry ,Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores] ,longitudinal analysis ,medicine.disease ,técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes::estudios de seguimiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Sistema cardiovascular - Malalties - Imatgeria ,chronic coronary artery disease ,Heart failure ,business - Abstract
Enfermedad arterial coronaria crónica; Análisis longitudinal; Planificar el seguimiento Malaltia arterial coronària crònica; Anàlisi longitudinal; Planificar el seguiment Chronic coronary artery disease; Longitudinal analysis; Planning the follow-up Cardiovascular disease remains the leading cause of death among Europeans, Americans, and around the world. In addition, the prevalence of coronary artery disease (CAD) is increasing, with the highest number of hospital visits, hospital readmissions for patients with decompensated heart failure, and a high economic cost. It is, therefore, a priority to try to plan the follow-up of patients with stable chronic CAD (scCAD) in relation to the published data, experience, and new technology that we have today. Planning the follow-up of patients with scCAD goes beyond the information provided by clinical management guidelines. It requires understanding the importance of a cross-sectional and longitudinal analysis in the clinical history of scCAD, because it has an impact on the cost of healthcare in relation to mortality, economic factors, and the burden of medical consultations. Using the data provided in this work facilitates and standardizes the clinical follow-up of patients with scCAD, and following the marked line makes the work for the clinical physician much easier, by including most clinical possibilities and actions to consider. The follow-up intervals vary according to the clinical situation of each patient and can be highly variable. In addition, the ability to properly study patients with imaging techniques, to stratify at different levels of risk, helps plan the intervals during follow-up. Given the complexity of coronary artery disease and the diversity of clinical cases, more studies are required in the future focused on improving the planning of follow-up for patients with scCAD. The perspective and future direction are related to the valuable utility of integrated imaging techniques in clinical follow-up. This research received no external funding.
- Published
- 2021
- Full Text
- View/download PDF
38. Protective Role of Nrf2 in Renal Disease
- Author
-
Sandra Rayego-Mateos, José Luis Morgado-Pascual, Javier Egea, Sebastian Mas, José M. Villalba, Alfonso Rubio-Navarro, Lucas Opazo-Ríos, Alejandra Palomino-Antolín, Jesús Egido, Cristina García-Caballero, Melania Guerrero-Hue, Alberto Ortiz, Juan Antonio Moreno, Carmen Herencia, Cristina Vázquez-Carballo, UAM. Departamento de Medicina, [Guerrero-Hue,M, Rayego-Mateos,S, García-Caballero,C, Morgado-Pascual,JL, Moreno,JA] Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain. [Vázquez-Carballo,C, Opazo-Rios,L, Herencia,C, Mas,S, Ortiz,A, Egido,J] Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Autónoma University, Madrid, Spain. [Palomino-Antolín,A, Egea,J] Research Unit, Hospital Universitario Santa Cristina, IIS-Hospital Universitario de la Princesa, Madrid, Spain. [Palomino-Antolín,A, Egea,J] Departament of Pharmacology and Therapeutics, Medicine Faculty, Instituto Teófilo Hernando, Autónoma University, Madrid, Spain. [Opazo-Rios,L, Egido,J] Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. [Ortiz,A] Red Nacional Investigaciones Nefrológicas (REDINREN), Madrid, Spain. [Rubio-Navarro,A] Weill Center for Metabolic Health and Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. [Villalba,JM, Moreno,JA] Department of Cell Biology, Physiology, and Immunology, Agrifood Campus of International Excellence (ceiA3), University of Cordoba, Cordoba, Spain. [Moreno,JA] Hospital Universitario Reina Sofia, Cordoba, Spain. [Moreno,JA] Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), Madrid, Spain., and The authors’ work has been supported by grants FIS/Fondos FEDER (PI17/00130, PI17/00257, PI17/01495, PI18/01386, PI19/00815, PI20/00375, PI20/00487 ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-098788-B-100, DTS17/00203, DTS19/00093, RYC-2017-22369, FJC2019-042028), The 'PFIS'and 'Sara Borrell' training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021), and CH-B (CP16/00017). Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) grant RTI2018-100695-B-I00, Junta de Andalucía grants P18-RT-4264, 1263735-R and BIO-276, the FEDER Funding Program from the European Union, and Universidad de Córdoba (to J.M.V.). No other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
- Subjects
0301 basic medicine ,Anatomy::Urogenital System::Urinary Tract::Kidney [Medical Subject Headings] ,Physiology ,Clinical Biochemistry ,Review ,Disease ,Bioinformatics ,medicine.disease_cause ,urologic and male genital diseases ,Biochemistry ,environment and public health ,Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic [Medical Subject Headings] ,and inflammatory response ,Lesión renal aguda ,0302 clinical medicine ,Factor 1 relacionado con NF-E2 ,Phenomena and Processes::Metabolic Phenomena::Metabolism::Oxidative Stress [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Cause of Death [Medical Subject Headings] ,Cause of death ,Acute kidney injury ,Estrés oxidativo ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Basic-Leucine Zipper Transcription Factors::NF-E2-Related Factor 2 [Medical Subject Headings] ,respiratory system ,030220 oncology & carcinogenesis ,Diseases::Female Urogenital Diseases and Pregnancy Complications::Female Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [Medical Subject Headings] ,medicine.symptom ,Medicina ,Inflammation ,Nrf2 ,Renal disease ,03 medical and health sciences ,Enfermedades renales ,medicine ,Molecular Biology ,Transcription factor ,Inflamación ,business.industry ,lcsh:RM1-950 ,Inflammatory response ,Cell Biology ,medicine.disease ,Clinical trial ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,Oxidative stress ,business ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings] ,Kidney disease - Abstract
Chronic kidney disease (CKD) is one of the fastest-growing causes of death and is predicted to become by 2040 the fifth global cause of death. CKD is characterized by increased oxidative stress and chronic inflammation. However, therapies to slow or prevent CKD progression remain an unmet need. Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that plays a key role in protection against oxidative stress and regulation of the inflammatory response. Consequently, the use of compounds targeting Nrf2 has generated growing interest for nephrologists. Pre-clinical and clinical studies have demonstrated that Nrf2-inducing strategies prevent CKD progression and protect from acute kidney injury (AKI). In this article, we review current knowledge on the protective mechanisms mediated by Nrf2 against kidney injury, novel therapeutic strategies to induce Nrf2 activation, and the status of ongoing clinical trials targeting Nrf2 in renal diseases, The authors’work has been supported by grants FIS/Fondos FEDER (PI17/00130, PI17/00257, PI17/01495, PI18/01386, PI19/00815, PI20/00375, PI20/00487 ISCIII-RETIC REDinREN RD016/0009), Sociedad Española de Nefrología, FRIAT, Comunidad de Madrid en Biomedicina B2017/BMD-3686 CIFRA2-CM. Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Spanish Ministry of Science and Innovation (RTI2018-098788-B-100, DTS17/00203, DTS19/00093, RYC-2017-22369, FJC2019-042028), The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310), SR-M (CD19/00021), and CH-B (CP16/00017). Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) grant RTI2018-100695-B-I00, Junta de Andalucía grants P18-RT-4264, 1263735-R and BIO-276, the FEDER Funding Program from the European Union, and Universidad de Córdoba (to J.M.V.)
- Published
- 2020
39. Opposite effects of moderate and extreme Cx43 deficiency in conditional Cx43-deficient mice on angiotensin II-induced cardiac fibrosis
- Author
-
Valls de Lacalle, Laura, Rodríguez, Cristina, Negre-Pujol, Corall, Varona, Saray, Antoni Valera Cañellas, Consegal, Marta, Martínez-González, Jose, Rodríguez-Sinovas, Antonio, Universitat Autònoma de Barcelona, [Valls-Lacalle L, Negre-Pujol C, Valera-Cañellas A, Consegal M, Rodríguez-Sinovas A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Rodríguez C] Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Institut de Recerca del Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain. [Varona S] Centro de Investigación Biomédica en Red sobre Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Instituto de Investigaciones Biomédicas de Barcelona (IIBB-CSIC), Barcelona, Spain. Institut de Recerca del Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Fundació La Marató de TV3, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Generalitat de Catalunya, Rodríguez, Cristina [0000-0002-6472-5647], Rodríguez-Sinovas, Antonio [0000-0003-2930-8773], Rodríguez, Cristina, and Rodríguez-Sinovas, Antonio
- Subjects
0301 basic medicine ,collagen ,Cardiac fibrosis ,Connexin ,Muscle Proteins ,030204 cardiovascular system & hematology ,angiotensin ii ,Muscle hypertrophy ,connexin 43 ,Mice ,0302 clinical medicine ,Fibrosis ,Macrophage ,lcsh:QH301-705.5 ,Mice, Knockout ,Chemistry ,Angiotensin II ,Cell Differentiation ,General Medicine ,Eukaryota::animales::grupos de población animal::animales modificados genéticamente::ratones transgénicos::ratones noqueados [ORGANISMOS] ,Cardiovascular Diseases::Heart Diseases::Cardiomyopathies [DISEASES] ,cardiovascular system ,Collagen ,biological phenomena, cell phenomena, and immunity ,Cardiomyopathies ,hypertrophy ,hormones, hormone substitutes, and hormone antagonists ,medicine.medical_specialty ,p38 mitogen-activated protein kinases ,Miocardi - Malalties ,Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Membrane Transport Proteins::Connexins::Connexin 43 [CHEMICALS AND DRUGS] ,Article ,Eukaryota::Animals::Animal Population Groups::Animals, Genetically Modified::Mice, Transgenic::Mice, Knockout [ORGANISMS] ,03 medical and health sciences ,Internal medicine ,medicine ,aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::proteínas de transporte de membrana::conexinas::conexina 43 [COMPUESTOS QUÍMICOS Y DROGAS] ,Animals ,Myocardium ,fibrosis ,Hypertrophy ,Fibroblasts ,medicine.disease ,Connexines ,030104 developmental biology ,Endocrinology ,lcsh:Biology (General) ,Connexin 43 ,enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías [ENFERMEDADES] ,Myocardial fibrosis ,sense organs ,Models animals en la investigació - Abstract
Connexin 43 (Cx43) is essential for cardiac electrical coupling, but its effects on myocardial fibrosis is controversial. Here, we analyzed the role of Cx43 in myocardial fibrosis caused by angiotensin II (AngII) using Cx43fl/fl and Cx43Cre-ER(T)/fl inducible knock-out (Cx43 content: 50%) mice treated with vehicle or 4-hydroxytamoxifen (4-OHT) to induce a Cre-ER(T)-mediated global deletion of the Cx43 floxed allele. Myocardial collagen content was enhanced by AngII in all groups (n = 8&ndash, 10/group, p <, 0.05). However, animals with partial Cx43 deficiency (vehicle-treated Cx43Cre-ER(T)/fl) had a significantly higher AngII-induced collagen accumulation that reverted when treated with 4-OHT, which abolished Cx43 expression. The exaggerated fibrotic response to AngII in partially deficient Cx43Cre-ER(T)/fl mice was associated with enhanced p38 MAPK activation and was not evident in Cx43 heterozygous (Cx43+/-) mice. In contrast, normalization of interstitial collagen in 4-OHT-treated Cx43Cre-ER(T)/fl animals correlated with enhanced MMP-9 activity, IL-6 and NOX2 mRNA expression, and macrophage content, and with reduced &alpha, SMA and SM22&alpha, in isolated fibroblasts. In conclusion, our data demonstrates an exaggerated, p38 MAPK-dependent, fibrotic response to AngII in partially deficient Cx43Cre-ER(T)/fl mice, and a paradoxical normalization of collagen deposition in animals with an almost complete Cx43 ablation, an effect associated with increased MMP-9 activity and inflammatory response and reduced fibroblasts differentiation.
- Published
- 2019
40. Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion
- Author
-
David Garcia-Dorado, Federico Mayor, Javier Inserte, Antonio Rodríguez-Sinovas, Petronila Penela, Paula Ramos, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (España), European Commission, Comunidad de Madrid, Fundación Ramón Areces, UAM. Departamento de Biología Molecular, [Penela P, Mayor Jr F] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. [Inserte J, Rodriguez-Sinovas A, Garcia-Dorado D] CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Ramos P] Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (UAM-CSIC), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Male ,0301 basic medicine ,Research paper ,G-Protein-Coupled Receptor Kinase 2 ,Swine ,Myocardial Ischemia ,Cardioprotection ,Pharmacology ,enfermedades cardiovasculares::enfermedades cardíacas::enfermedades cardiovasculares::enfermedades cardíacas::isquemia miocárdica::enfermedades cardiovasculares::enfermedades cardiovasculares::daño por reperfusión miocárdica [ENFERMEDADES] ,RISK, reperfusion injury salvage kinase pathway ,HF, heart failure ,aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intracelular::cinasas de receptores acoplados a proteína G::cinasas de receptores adrenérgicos beta::aminoácidos, péptidos y proteínas::cinasa 2 del receptor acoplado a proteína G [COMPUESTOS QUÍMICOS Y DROGAS] ,0302 clinical medicine ,Cardiovascular Diseases::Heart Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Cardiovascular Diseases::Cardiovascular Diseases::Myocardial Reperfusion Injury [DISEASES] ,Phosphorylation ,Cells, Cultured ,Amino Acids, Peptides, and Proteins::Amino Acids, Peptides, and Proteins::Proteins::Intracellular Signaling Peptides and Proteins::G-Protein-Coupled Receptor Kinases::beta-Adrenergic Receptor Kinases::G-Protein-Coupled Receptor Kinase 2 [CHEMICALS AND DRUGS] ,biology ,Ischemia-reperfusion ,Calpain ,General Medicine ,Reperfusió miocardíaca ,Biología y Biomedicina / Biología ,metabolismo ,030220 oncology & carcinogenesis ,Proteïna quinasa CK2 ,MI, myocardial infarction ,Signal transduction ,Oxidation-Reduction ,Proteasome Endopeptidase Complex ,Ischemia ,Calpains ,GRK2, G-protein coupled receptor kinase 2 ,GRK2 ,Myocardial Reperfusion Injury ,Models, Biological ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,Pin1 ,medicine ,Animals ,Protein kinase B ,PI3K/AKT/mTOR pathway ,Adaptor Proteins, Signal Transducing ,Proteasome ,business.industry ,Beta adrenergic receptor kinase ,AKT ,metabolism ,medicine.disease ,Rats ,Disease Models, Animal ,030104 developmental biology ,GPCR, G-protein coupled receptor ,Proteolysis ,biology.protein ,I/R, Ischemia/Reperfusion ,Models animals en la investigació ,Investigative Techniques::Models, Animal::Investigative Techniques::Disease Models, Animal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,técnicas de investigación::modelos animales::técnicas de investigación::modelos de enfermedad en animales [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,business ,Proto-Oncogene Proteins c-akt ,Biomarkers - Abstract
Background: Identification of signaling pathways altered at early stages after cardiac ischemia/reperfusion (I/R) is crucial to develop timely therapies aimed at reducing I/R injury. The expression of G protein-coupled receptor kinase 2 (GRK2), a key signaling hub, is up-regulated in the long-term in patients and in experimental models of heart failure. However, whether GRK2 levels change at early time points following myocardial I/R and its functional impact during this period remain to be established. Methods: We have investigated the temporal changes of GRK2 expression and their potential relationships with the cardioprotective AKT pathway in isolated rat hearts and porcine preclinical models of I/R. Findings: Contrary to the maladaptive up-regulation of GRK2 reported at later times after myocardial infarction, successive GRK2 phosphorylation at specific sites during ischemia and early reperfusion elicits GRK2 degradation by the proteasome and calpains, respectively, thus keeping GRK2 levels low during early I/R in rat hearts. Concurrently, I/R promotes decay of the prolyl-isomerase Pin1, a positive regulator of AKT stability, and a marked loss of total AKT protein, resulting in an overall decreased activity of this pro-survival pathway. A similar pattern of concomitant down-modulation of GRK2/AKT/Pin1 protein levels in early I/R was observed in pig hearts. Calpain and proteasome inhibition prevents GRK2/Pin1/AKT degradation, restores bulk AKT pathway activity and attenuates myocardial I/R injury in isolated rat hearts. Interpretation: Preventing transient degradation of GRK2 and AKT during early I/R might improve the potential of endogenous cardioprotection mechanisms and of conditioning strategies., Instituto de Salud Carlos III, Spain (grant PI-16/00232; RETICS-RIC-RD12/0042/0021 to DGD, cofunded with European Regional Development Fund-FEDER contribution, and grants PI14-00435 and PI17-00576 to PP), by Ministerio de Economía; Industria y Competitividad (MINECO) of Spain (grant SAF2017-84125-R to F.M.); by CIBERCV-Instituto de Salud Carlos III, Spain (grant CB16/11/00479 to DGD and CB16/11/00278 to F.M, cofunded with European Regional Development Fund-FEDER contribution), and Programa de Actividades en Biomedicina de la Comunidad de Madrid-B2017/BMD-3671-INFLAMUNE to F.M. We also acknowledge institutional support to the CBMSO from Fundación Ramón Areces
- Published
- 2019
41. Overexpression of scavenger receptor and infiltration of macrophage in epicardial adipose tissue of patients with ischemic heart disease and diabetes
- Author
-
José M. Melero, Concepción Santiago-Fernández, Luis Morcillo-Hidalgo, Lourdes Garrido-Sánchez, Amalio Ruiz-Salas, Mercedes Millán-Gómez, Fernando Carrasco-Chinchilla, Manuel F. Jiménez-Navarro, Inmaculada Moreno-Santos, Luis M. Pérez-Belmonte, [Santiago-Fernández,C, Garrido-Sánchez,L] Department of Endocrinology and Nutrition, Virgen de la Victoria Hospital (IBIMA), Malaga University, Malaga, Spain. [Santiago-Fernández,C, Garrido-Sánchez,L] Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Malaga, Spain. [Pérez-Belmonte,LM, Millán-Gómez,M, Moreno-Santos,I, Carrasco-Chinchilla,F, Ruiz-Salas,A, Morcillo-Hidalgo,L, Melero,JM, Jiménez-Navarro,M] Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Malaga, Spain. [Pérez-Belmonte,LM, Jiménez-Navarro,M] Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Malaga, Spain., and This work was supported by Grants from the Spanish Ministry of Health (FIS) (PI13/02542, PI11/01661) and Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV) (CB16/11/00360), Instituto de Salud Carlos III co-funded by the Fondo Europeo de Desarrollo Regional (FEDER).
- Subjects
Male ,0301 basic medicine ,endocrine system diseases ,Diabetic Cardiomyopathies ,CD36 ,Myocardial Ischemia ,lcsh:Medicine ,Coronary Artery Disease ,Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Movement [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,chemistry.chemical_compound ,Scavenger receptors ,0302 clinical medicine ,Diabetes mellitus ,Cell Movement ,Oxidized low-density lipoprotein ,Anatomy::Cardiovascular System::Heart::Pericardium [Medical Subject Headings] ,Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings] ,Receptors, Scavenger ,Chemicals and Drugs::Lipids::Lipoproteins::Lipoproteins, LDL [Medical Subject Headings] ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Scavenger [Medical Subject Headings] ,biology ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings] ,Oxidized low-density ,General Medicine ,Middle Aged ,Anatomy::Tissues::Connective Tissue::Adipose Tissue [Medical Subject Headings] ,Up-Regulation ,Lipoproteins, LDL ,Adipose Tissue ,030220 oncology & carcinogenesis ,Female ,Pericardium ,medicine.medical_specialty ,Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia [Medical Subject Headings] ,Ischemic heart disease ,Check Tags::Male [Medical Subject Headings] ,General Biochemistry, Genetics and Molecular Biology ,MSR1 ,03 medical and health sciences ,Internal medicine ,Anatomy::Cells::Connective Tissue Cells::Macrophages [Medical Subject Headings] ,Epicardial adipose tissue ,medicine ,Humans ,Scavenger receptor ,Coronary atherosclerosis ,CXCL16 ,Aged ,business.industry ,Research ,Macrophages ,lcsh:R ,Type 2 Diabetes Mellitus ,Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings] ,Diseases::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies::Diabetic Cardiomyopathies [Medical Subject Headings] ,Persons::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,medicine.disease ,030104 developmental biology ,Endocrinology ,Diabetes Mellitus, Type 2 ,chemistry ,Check Tags::Female [Medical Subject Headings] ,Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation::Up-Regulation [Medical Subject Headings] ,Diseases::Cardiovascular Diseases::Heart Diseases::Myocardial Ischemia::Coronary Disease::Coronary Artery Disease [Medical Subject Headings] ,Case-Control Studies ,biology.protein ,Glycated hemoglobin ,business - Abstract
Background Oxidized low-density lipoproteins and scavenger receptors (SRs) play an important role in the formation and development of atherosclerotic plaques. However, little is known about their presence in epicardial adipose tissue (EAT). The objective of the study was to evaluate the mRNA expression of different SRs in EAT of patients with ischemic heart disease (IHD), stratifying by diabetes status and its association with clinical and biochemical variables. Methods We analyzed the mRNA expression of SRs (LOX-1, MSR1, CXCL16, CD36 and CL-P1) and macrophage markers (CD68, CD11c and CD206) in EAT from 45 patients with IHD (23 with type 2 diabetes mellitus (T2DM) and 22 without T2DM) and 23 controls without IHD or T2DM. Results LOX-1, CL-P1, CD68 and CD11c mRNA expression were significantly higher in diabetic patients with IHD when compared with those without T2DM and control patients. MSR1, CXCL16, CD36 and CD206 showed no significant differences. In IHD patients, LOX-1 (OR 2.9; 95% CI 1.6–6.7; P = 0.019) and CD68 mRNA expression (OR 1.7; 95% CI 0.98–4.5; P = 0.049) were identified as independent risk factors associated with T2DM. Glucose and glycated hemoglobin were also shown to be risk factors. Conclusions SRs mRNA expression is found in EAT. LOX-1 and CD68 and were higher in IHD patients with T2DM and were identified as a cardiovascular risk factor of T2DM. This study suggests the importance of EAT in coronary atherosclerosis among patients with T2DM.
- Published
- 2019
42. Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention
- Author
-
Juan P. Rodriguez-Escudero, Abhiram Prasad, Daniel J. Crusan, Ray W. Squires, Luis M. Pérez-Belmonte, Kashish Goel, Randal J. Thomas, Carlos M Diaz-Melean, Francisco Lopez-Jimenez, Ryan J. Lennon, Manuel F. Jiménez-Navarro, [Jimenez-Navarro, Manuel F.] Univ Malaga, Inst Biomed Malaga, Hosp Univ Virgen de la Victoria, UGC Corazon,CIBERCV Enfermedades Cardiovasc, Malaga, Spain, [Perez-Belmonte, Luis M.] Univ Malaga, Inst Biomed Malaga, Hosp Univ Virgen de la Victoria, UGC Corazon,CIBERCV Enfermedades Cardiovasc, Malaga, Spain, [Lopez-Jimenez, Francisco] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Lennon, Ryan J.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Diaz-Melean, Carlos] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Rodriguez-Escudero, J. P.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Goel, Kashish] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Crusan, Daniel] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Prasad, Abhiram] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Squires, Ray W.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Thomas, Randal J.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA, [Lopez-Jimenez, Francisco] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Lennon, Ryan J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Diaz-Melean, Carlos] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Rodriguez-Escudero, J. P.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Goel, Kashish] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Crusan, Daniel] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Prasad, Abhiram] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Squires, Ray W.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, [Thomas, Randal J.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA, Mayo Clinic Division of Cardiovascular Disease, Instituto de Salud Carlos III (ISCIII) (Ministry of Economy and Competitiveness) (Spain) (Beca BAE), Spanish Ministry of Health, Spanish Cardiovascular Research Network, Fondo Europeo de Desarrollo Regional, Sociedad Andaluza de Cardiologia (Beca Estancia Extranjero), and Red de Investigacion Cardiovascular
- Subjects
Male ,Time Factors ,Survival ,medicine.medical_treatment ,Coronary Artery Disease ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Coronary artery disease ,0302 clinical medicine ,Risk Factors ,Cause of Death ,Cardiovascular Disease ,Secondary Prevention ,030212 general & internal medicine ,Myocardial infarction ,Preventive Cardiology ,Original Research ,Aged, 80 and over ,Cardiac Rehabilitation ,Mortality rate ,Hazard ratio ,Diabetes, Type 2 ,Middle Aged ,Treatment Outcome ,diabetes mellitus ,Female ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Minnesota ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Internal medicine ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Humans ,Mortality ,Propensity Score ,Aged ,Retrospective Studies ,Chi-Square Distribution ,business.industry ,percutaneous coronary intervention ,Percutaneous coronary intervention ,medicine.disease ,Confidence interval ,Surgery ,Myocardial-infarction ,cardiac rehabilitation ,Logistic Models ,Propensity score matching ,Multivariate Analysis ,Patient Compliance ,business - Abstract
Background Participation in cardiac rehabilitation ( CR ) is an essential component of care for patients with coronary artery disease. However, little is known about its benefit on cardiovascular outcomes in patients with diabetes mellitus ( DM ) who have undergone percutaneous coronary intervention. The aim of our study was to evaluate the impact of CR in this high‐risk group of patients. Methods and Results We performed a retrospective analysis of all patients with DM who underwent percutaneous coronary intervention in Olmsted County (Minnesota) between 1994 and 2010, assessing the impact of CR participation on clinical outcomes. CR participation was significantly lower in patients with DM (38%, 263/700) compared with those who did not have DM (45%, 1071/2379; P =0.004). Using propensity score adjustment, we found that in patients with DM , CR participation was associated with significantly reduced all‐cause mortality (hazard ratio, 0.56; 95% confidence interval, 0.39–0.80; P =0.002) and composite end point of mortality, myocardial infarction, or revascularization (hazard ratio, 0.77; 95% confidence interval, 0.60–0.98; P =0.037), during a median follow‐up of 8.1 years. In patients without DM , CR participation was associated with a significant reduction in all‐cause mortality (hazard ratio, 0.67; 95% confidence interval, 0.55–0.82; P P =0.024). Conclusions CR participation after percutaneous coronary intervention is associated with lower all‐cause mortality rates in patients with DM , to a similar degree as for those without DM . However, CR participation was lower in patients with DM , suggesting the need to identify and correct the barriers to CR participation for this higher‐risk group of patients.
- Published
- 2017
43. Natural History and Clinical Predictors of Atrial Tachycardia in Adults With Congenital Heart Disease
- Author
-
Ana Campos, José Ruiz-Cantador, Raquel Prieto, Ana Elvira González-García, Pablo Ávila, Francisco Fernández-Avilés, Pastora Gallego, Raquel Yotti, Esther Cambronero, José M. Oliver, Fernando Sarnago, María José Rodríguez-Puras, Rafael Peinado, [Avila, Pablo] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Maria Oliver, Jose] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Peinado, Rafael] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Sarnago, Fernando] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Yotti, Raquel] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Fernandez-Aviles, Francisco] Univ Complutense Madrid, Fac Med, IiSGM, Dept Cardiol,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Avila, Pablo] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Maria Oliver, Jose] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Peinado, Rafael] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Sarnago, Fernando] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Yotti, Raquel] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Fernandez-Aviles, Francisco] Univ Complutense Madrid, Fac Med, IiSGM, CIBERCV,Hosp Gen Univ Gregorio Maranon, Madrid, Spain, [Maria Oliver, Jose] Hosp Univ La Paz, Adult Congenital Heart Dis Unit, Madrid, Spain, [Gonzalez-Garcia, Ana] Hosp Univ La Paz, Adult Congenital Heart Dis Unit, Madrid, Spain, [Cambronero, Esther] Hosp Univ La Paz, Adult Congenital Heart Dis Unit, Madrid, Spain, [Ruiz-Cantador, Jose] Hosp Univ La Paz, Adult Congenital Heart Dis Unit, Madrid, Spain, [Prieto, Raquel] Hosp Univ La Paz, Adult Congenital Heart Dis Unit, Madrid, Spain, [Gallego, Pastora] Hosp Virgen Rocio & Virgen Macarena, Interctr Congenital Heart Dis Unit, Seville, Spain, [Jose Rodriguez-Puras, Maria] Hosp Virgen Rocio & Virgen Macarena, Interctr Congenital Heart Dis Unit, Seville, Spain, [Campos, Ana] Hosp Virgen Rocio & Virgen Macarena, Interctr Congenital Heart Dis Unit, Seville, Spain, Instituto de Salud Carlos III, Ministerio de Economia y Competividad, Spain, and Instituto de Salud Carlos III - European Regional Development Funds (ERDF)
- Subjects
Male ,Pediatrics ,Heart disease ,030204 cardiovascular system & hematology ,Arrhythmias ,Ablation ,0302 clinical medicine ,Intraatrial reentrant tachycardia ,Risk Factors ,Atrial Fibrillation ,Survival prospects ,Prevalence ,risk factors ,030212 general & internal medicine ,Registries ,Incidence (epidemiology) ,Incidence ,atrial tachycardia ,Flutter ,congenital heart disease ,Risk-factors ,medicine.anatomical_structure ,Great arteries ,Cohort ,Cardiology ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Fontan ,Adult ,Heart Defects, Congenital ,medicine.medical_specialty ,Adolescent ,03 medical and health sciences ,Predictive Value of Tests ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Septal-defects ,Atrial tachycardia ,business.industry ,Proportional hazards model ,medicine.disease ,Pulmonary hypertension ,Ventricle ,Spain ,Fibrillation ,incidence ,business - Abstract
Background Atrial tachycardias (ATs) are a significant source of morbidity in adults with congenital heart disease (CHD). This study evaluates the incidence and clinical predictors of AT in a cohort of patients with CHD. Methods and Results We included 3311 adults (median age at entry 22.6 years, 50.6% males) with CHD (49% simple, 39% moderate, and 12% complex) prospectively followed up in a tertiary center for 37 607 person-years. Predictors of AT were identified by multivariable Cox regression analysis accounting for left truncation. An external validation was performed in a contemporary cohort of 1432 patients. Overall, 153 (4.6%) patients presented AT. AT burden was highest in complex CHD, such as single ventricle (22.8%) and d -transposition of the great arteries (22.1%). Hazard rates of AT across lifetime, age at presentation, and the time lapse between surgery and the first AT episode varied among the most common CHD. Independent risk factors for developing AT were univentricular physiology, previous intracardiac repair, systemic right ventricle, pulmonary hypertension, pulmonary regurgitation, pulmonary atrioventricular valve regurgitation, pulmonary and systemic ventricular dysfunction. At the age of 40 years, AT-free survival in patients with 0, 1, 2, and ≥3 risk factors was 100%, 94%, 76%, and 50%, respectively. These findings were confirmed in the validation cohort. Conclusions Natural history of AT differed among the most common forms of CHD. Simple clinical parameters, easily obtained by noninvasive means, were independent predictors of AT in adults with CHD. Although risk was negligible in patients without any of these factors, their addition progressively increased AT burden.
- Published
- 2017
- Full Text
- View/download PDF
44. Cardiorenal benefits of finerenone: protecting kidney and heart
- Author
-
José R. González-Juanatey, Jose Luis Górriz, Alberto Ortiz, Alfonso Valle, Maria Jose Soler, Lorenzo Facila, Institut Català de la Salut, [González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES] ,Cardiovascular Diseases [DISEASES] ,Otros calificadores::/uso terapéutico [Otros calificadores] ,hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de receptores de mineralocorticoides [COMPUESTOS QUÍMICOS Y DROGAS] ,Diabetis no-insulinodependent - Complicacions ,enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica [ENFERMEDADES] ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [DISEASES] ,General Medicine ,Antihormones ,Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Mineralocorticoid Receptor Antagonists [CHEMICALS AND DRUGS] ,Insuficiència renal crònica - Complicacions ,Sistema cardiovascular - Malalties - Diagnòstic ,Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency, Chronic [DISEASES] ,Other subheadings::/therapeutic use [Other subheadings] ,enfermedades cardiovasculares [ENFERMEDADES] - Abstract
Albuminuria; Enfermedad renal crónica; Finerenona Albuminúria; Malaltia renal crònica; Finerenona Albuminuria; Chronic kidney disease; Finerenone Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view.
- Published
- 2023
- Full Text
- View/download PDF
45. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry
- Author
-
Abumayyaleh, Mohammad, Nuñez Gil, Ivan Javier, Viana-Llamas, María C., RAPOSEIRAS-ROUBIN, SERGIO, Romero, Rodolfo, Alfonso, Emilio, Uribarri, Aitor, Institut Català de la Salut, [Abumayyaleh M] Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg/Mannheim, Mannheim, Germany. [Núñez Gil IJ] Hospital Clínico San Carlos, Universidad Complutense de Madrid, Instituto de Investigación, Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Viana-LLamas MC] Hospital Universitario Guadalajara, Guadalajara, Spain. [Raposeiras Roubin S] University Hospital Álvaro Cunqueiro, Vigo, Spain. [Romero R] Hospital Universitario Getafe, Getafe, Universidad Europea, Madrid, Spain. [Alfonso-Rodríguez E] Hospital University of Bellvitge, Barcelona, Spain. [Uribarri A] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigacion Biomedica en Red para Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Diabetis ,enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus [ENFERMEDADES] ,virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES] ,Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES] ,COVID-19 (Malaltia) ,Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus [DISEASES] - Abstract
SARS-CoV-2; Reinfection; Respiratory complications SARS-CoV-2; Reinfección; Complicaciones respiratorias SARS-CoV-2; Reinfecció; Complicacions respiratòries Background: Diabetes mellitus (DM) is one of the most frequent comorbidities in patients suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a higher rate of severe course of coronavirus disease (COVID-19). However, data about post-COVID-19 syndrome (PCS) in patients with DM are limited. Methods: This multicenter, propensity score-matched study compared long-term follow-up data about cardiovascular, neuropsychiatric, respiratory, gastrointestinal, and other symptoms in 8,719 patients with DM to those without DM. The 1:1 propensity score matching (PSM) according to age and sex resulted in 1,548 matched pairs. Results: Diabetics and nondiabetics had a mean age of 72.6 ± 12.7 years old. At follow-up, cardiovascular symptoms such as dyspnea and increased resting heart rate occurred less in patients with DM (13.2% vs. 16.4%; p = 0.01) than those without DM (2.8% vs. 5.6%; p = 0.05), respectively. The incidence of newly diagnosed arterial hypertension was slightly lower in DM patients as compared to non-DM patients (0.5% vs. 1.6%; p = 0.18). Abnormal spirometry was observed more in patients with DM than those without DM (18.8% vs. 13; p = 0.24). Paranoia was diagnosed more frequently in patients with DM than in non-DM patients at follow-up time (4% vs. 1.2%; p = 0.009). The incidence of newly diagnosed renal insufficiency was higher in patients suffering from DM as compared to patients without DM (4.8% vs. 2.6%; p = 0.09). The rate of readmission was comparable in patients with and without DM (19.7% vs. 18.3%; p = 0.61). The reinfection rate with COVID-19 was comparable in both groups (2.9% in diabetics vs. 2.3% in nondiabetics; p = 0.55). Long-term mortality was higher in DM patients than in non-DM patients (33.9% vs. 29.1%; p = 0.005). Conclusions: The mortality rate was higher in patients with DM type II as compared to those without DM. Readmission and reinfection rates with COVID-19 were comparable in both groups. The incidence of cardiovascular symptoms was higher in patients without DM.
- Published
- 2023
46. Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca2+ Handling and NRF2 Activation
- Author
-
Almudena Val-Blasco, Patricia Prieto, Rafael Iñigo Jaén, Marta Gil-Fernández, Marta Pajares, Nieves Domenech, Verónica Terrón, María Tamayo, Inmaculada Jorge, Jesús Vázquez, Andrea Bueno-Sen, María Teresa Vallejo-Cremades, Jorge Pombo-Otero, Sergio Sanchez-García, Gema Ruiz-Hurtado, Ana María Gómez, Carlos Zaragoza, María Generosa Crespo-Leiro, Eduardo López-Collazo, Antonio Cuadrado, Carmen Delgado, Lisardo Boscá, María Fernández-Velasco, Ministerio de Economía y Competitividad (España), Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Instituto de Salud Carlos III, Sociedad Española de Cardiología, Unión Europea. Fondo Social Europeo (ESF/FSE), Centro de Investigación Biomédica en Red - CIBERCV (Enfermedades Cardiovasculares), Ministerio de Ciencia, Innovación y Universidades (España), Fundación La Caixa, Agencia Estatal de Investigación (España), and Fundación 'la Caixa'
- Subjects
Myocarditis ,Pro-resolving mediators ,Calcium handling ,SERCA2A ,Cardiology and Cardiovascular Medicine ,NRF2 - Abstract
Specialized proresolving mediators and, in particular, 5(S), (6)R, 7-trihydroxyheptanoic acid methyl ester (BML-111) emerge as new therapeutic tools to prevent cardiac dysfunction and deleterious cardiac damage associated with myocarditis progression. The cardioprotective role of BML-111 is mainly caused by the prevention of increased oxidative stress and nuclear factor erythroid-derived 2-like 2 (NRF2) down-regulation induced by myocarditis. At the molecular level, BML-111 activates NRF2 signaling, which prevents sarcoplasmic reticulum–adenosine triphosphatase 2A down-regulation and Ca2+ mishandling, and attenuates the cardiac dysfunction and tissue damage induced by myocarditis., This work was supported by the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (SAF-2017-84777R), Instituto de Salud Carlos III (ISCIII) (PI17/01093, PI17/01344, and PI20/01482), Sociedad Española de Cardiología, Proyecto Traslacional 2019 and Asociación del Ritmo Cardiaco (SEC, España), Proyecto Asociación Insuficiencia Cardiaca (Trasplante Cardiaco) 2020, Fondo Europeo de Desarrollo Regional, Fondo Social Europeo, and CIBERCV, a network funded by ISCIII, Spanish Ministry of Science, Innovation and Universities (PGC2018-097019-B-I00), Ministerio de Economía, Industria y Competitividad/Agencia Estatal de Investigación 10.13039/501100011033 PID2020-113238RB-I00, PID2019-105600RB-I00, the Instituto de Salud Carlos III (Fondo de Investigación Sanitaria grant PRB3 [PT17/0019/0003-ISCIII-SGEFI/ERDF, ProteoRed]), and “la Caixa” Foundation (project code HR17-00247). The Centro Nacional de Investigaciones Cardiovasculares is supported by the ISCIII, the Ministerio de Ciencia, Innovación y Universidades. Dr Ruiz-Hurtado is Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). Dr Tamayo and R.I. Jaén, and M. Gil-Fernández were or currently are PhD students funded by the Formación de Profesorado Universitario program of the Spanish Ministry of Science, Innovation and Universities (FPU17/06135; FPU16/00827, FPU1901973).
- Published
- 2022
- Full Text
- View/download PDF
47. Gender analysis of the frequency and course of depressive disorders and relationship with personality traits in general population: A prospective cohort study
- Author
-
Domènec Serrano, Ruth Martí-Lluch, Mérida Cárdenas, Pascual Solanas, Jaume Marrugat, Joan Vilalta-Franch, Josep Garre-Olmo, [Serrano D] Institut de Recerca Biomèdica de Girona (IDIBGI), Salt, Spain. Institut d'Assistència Sanitària, Salt, Spain. Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. [Martí-Lluch R] Institut de Recerca Biomèdica de Girona (IDIBGI), Salt, Spain. Grup de Recerca en Salut Vascular (ISV-Girona), Fundació Institut Universitari d'Investigació en Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain. [Cárdenas M] Servei de Cardiologia, Hospital Dr. Josep Trueta, Girona, Spain. [Solanas P] Departament de Ciències Mèdiques, Facultat de Medicina, Universitat de Girona, Girona, Spain. Grup de Recerca en Salut Vascular (ISV-Girona), Fundació Institut Universitari d'Investigació en Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain. [Marrugat J] Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. CIBERCV de recerca en Malalties Cardiovasculars, Madrid, Spain. [Vilalta-Franch J] Institut de Recerca Biomèdica de Girona (IDIBGI), Salt, Spain. [Garre-Olmo J] Institut de Recerca Biomèdica de Girona (IDIBGI), Salt, Spain. Institut d'Assistència Sanitària, Salt, Spain, and Institut d'Assistència Sanitària
- Subjects
Adult ,Male ,Depressive Disorder, Major ,Depression ,Epidemiology ,Incidence ,Behavioral Disciplines and Activities::Psychological Tests::Patient Health Questionnaire [PSYCHIATRY AND PSYCHOLOGY] ,Population ,Qüestionaris ,Behavioral Disciplines and Activities::Psychological Tests::Personality Tests [PSYCHIATRY AND PSYCHOLOGY] ,Psychiatry and Mental health ,Clinical Psychology ,Mental depression ,conducta y mecanismos de la conducta::conducta::síntomas conductuales::depresión [PSIQUIATRÍA Y PSICOLOGÍA] ,Surveys and Questionnaires ,Sex differences ,Humans ,disciplinas y actividades conductuales::pruebas psicológicas::cuestionario de salud del paciente [PSIQUIATRÍA Y PSICOLOGÍA] ,Female ,Prospective Studies ,Depressió psíquica ,Personalitat ,Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [PSYCHIATRY AND PSYCHOLOGY] ,disciplinas y actividades conductuales::pruebas psicológicas::pruebas de personalidad [PSIQUIATRÍA Y PSICOLOGÍA] ,Personality - Abstract
Depressió; Epidemiologia; Personalitat Depresión; Epidemiología; Personalidad Depression; Epidemiology; Personality Background: We aimed to determine the prevalence and course of subthreshold depressive symptomatology (sDS) and probable major depressive episode (MDE) and to examine their association with personality traits among men and women. Methods: A community-based sample aged 35 years or older was examined in two waves (median follow-up of 6.9 years). The Patient Health Questionnaire-9 (PHQ-9) was used to assess sDS and MDE. The 10-item version of the Big Five Inventory was used to assess personality traits. Prevalence was assessed at baseline (n=5,557) and incidence and persistence-recurrence rates were computed at follow up (n=3,102). Logistic regression models were adjusted to explore the association of personality traits with prevalence and course of depressive disorders. Results: The prevalence of sDS and MDE was 14.04% (95% CI = 17.04-19.08) and 8.54 (95% CI=7.82-9.31), the incidence was 14.30 per 1,000 person-years (95% CI=12.49-16.31) and 4.34 per 1,000 person-years (95% CI=3.46-5.36), and the persistence-recurrence was 35.04 per 1,000 person-years (95% CI=29.00-41.96) and 28.8 per 1,000 person-years (95% CI=20.49-38.14). The gender gap was higher for MDE. Personality traits were differentially associated with the prevalence and course of depressive disorders between men and women. Limitations: Because this study used questionnaires to assess depressive disorders and personality traits, information bias could not be ruled out. Conclusions: The gender gap was higher for the prevalence and course of the probable MDE. There were more personality traits related with the course of the sDS and they had a major role in the course of the probable MDE in women. This study was supported by research grant STL006/17/00234 from the Strategic Plan for Health Research and Innovation (PERIS) 2016-2020 of the Department of Health. Government of Catalunya.
- Published
- 2022
- Full Text
- View/download PDF
48. Cardiac protection induced by urocortin-2 enables the regulation of apoptosis and fibrosis after ischemia and reperfusion involving miR-29a modulation
- Author
-
Isabel Mayoral-González, Eva M. Calderón-Sánchez, Isabel Galeano-Otero, Marta Martín-Bórnez, Encarnación Gutiérrez-Carretero, María Fernández-Velasco, Nieves Domenech, María Generosa Crespo-Leiro, Ana María Gómez, Antonio Ordóñez-Fernández, Abdelkrim Hmadcha, Tarik Smani, Universidad de Sevilla / University of Sevilla, Biomedicine Institute of Sevilla [Seville, Spain], Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares [Spain] (CIBERCV), La Paz University Hospital, Universidade da Coruña, Signalisation et physiopathologie cardiovasculaire (CARPAT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, University of Alicante [Spain], Universidad Pablo de Olavide [Sevilla] (UPO), Gomez, Ana Maria, European Commission, Agencia Estatal de Investigación (España), Instituto de Salud Carlos III, Junta de Andalucía, and Agence Nationale de la Recherche (France)
- Subjects
fibrosis ,apoptosis ,heart failure ,Heart failure ,Apoptosis ,RM1-950 ,Fibrosis ,Ischemia and reperfusion ,[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Ucn-2 ,Drug Discovery ,ischemia and reperfusion ,Molecular Medicine ,Therapeutics. Pharmacology ,cardiac remodeling ,miRNA ,Cardiac remodeling - Abstract
Urocortin-2 (Ucn-2) has demonstrated cardioprotective actions against myocardial ischemia-reperfusion (I/R) injuries. Herein, we explored the protective role of Ucn-2 through microRNAs (miRNAs) post-transcriptional regulation of apoptotic and pro-fibrotic genes. We determined that the intravenous administration of Ucn-2 before heart reperfusion in a Wistar rat model of I/R recovered cardiac contractility and decreased fibrosis, lactate dehydrogenase release, and apoptosis. The infusion of Ucn-2 also inhibited the upregulation of 6 miRNAs in revascularized heart. The in silico analysis indicated that miR-29a and miR-451_1∗ are predicted to target many apoptotic and fibrotic genes. Accordingly, the transfection of neonatal rat ventricular myocytes with mimics overexpressing miR-29a, but not miR-451_1∗, prevented I/R-induced expression of pro- and anti-apoptotic genes such as Apaf-1, Hmox-1, and Cycs, as well as pro-fibrotic genes Col-I and Col-III. We also confirmed that Hmox-1, target of miR-29a, is highly expressed at the mRNA and protein levels in adult rat heart under I/R, whereas, Ucn-2 abolished I/R-induced mRNA and protein upregulation of HMOX-1. Interestingly, a significant upregulation of Hmox-1 was observed in the ventricle of ischemic patients with heart failure, correlating negatively with the left ventricle ejection fraction. Altogether, these data indicate that Ucn-2, through miR-29a regulation, provides long-lasting cardioprotection, involving the post-transcriptional regulation of apoptotic and fibrotic genes., This study was co-financed by FEDER Funds [US-1381135], Agencia Estatal de Investigación [PID2019-104084GB-C22/AEI/10.13039/501100011033]; the Institute of Carlos III [PI18/01197; Red TerCel-Grant RD16/0011/0034]; the Andalusia Government [grant number: PI-0193-2018]; and by Agence National de la Recherche [ANR-19-14-0031-01].
- Published
- 2022
- Full Text
- View/download PDF
49. Characterization of Seminal Microbiome of Infertile Idiopathic Patients Using Third-Generation Sequencing Platform
- Author
-
Sergio Garcia-Segura, Javier del Rey, Laia Closa, Iris Garcia-Martínez, Carlos Hobeich, Ana Belén Castel, Francisco Vidal, Jordi Benet, Maria Oliver-Bonet, Institut Català de la Salut, [Garcia-Segura S, Del Rey J] Unit of Cell Biology and Medical Genetics, Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Closa L] Histocompatibility and Immunogenetics Laboratory, Banc de Sang i Teixits (BST), Barcelona, Spain. Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. [Garcia-Martínez I, Hobeich C] Grup de Recerca de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Coagulopaties Congènites, Banc de Sang i Teixits (BST), Barcelona, Spain. [Castel AB] Instituto de Fertilidad, Palma de Mallorca, Spain. [Vidal F] Grup de Recerca de Medicina Transfusional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Grup de Coagulopaties Congènites, Banc de Sang i Teixits (BST), Barcelona, Spain. CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Otros calificadores::Otros calificadores::/genética [Otros calificadores] ,Organic Chemistry ,General Medicine ,Male Urogenital Diseases::Genital Diseases, Male::Infertility [DISEASES] ,Esterilitat ,Bacteris ,Catalysis ,Computer Science Applications ,Inorganic Chemistry ,fenómenos microbiológicos::microbiota [FENÓMENOS Y PROCESOS] ,Other subheadings::Other subheadings::/genetics [Other subheadings] ,Physical and Theoretical Chemistry ,Microbiological Phenomena::Microbiota [PHENOMENA AND PROCESSES] ,enfermedades urogenitales masculinas::enfermedades de los genitales masculinos::infertilidad [ENFERMEDADES] ,Molecular Biology ,seminal microbiota ,MinION ,nanopore sequencing ,Illumina ,male fertility ,Genètica ,Spectroscopy - Abstract
Male fertility; Nanopore sequencing; Seminal microbiota Fertilitat masculina; Seqüenciació de nanopors; Microbiota seminal Fertilidad masculina; Secuenciación de nanoporos; Microbiota seminal Since the first description of a commensal seminal microbiome using sequencing, less than a decade ago, interest in the composition of this microbiome and its relationship with fertility has been growing. Articles using next-generation sequencing techniques agree on the identification of the most abundant bacterial phyla. However, at the genus level, there is still no consensus on which bacteria are most abundant in human seminal plasma. This discrepancy may be due to methodological variability such as sample collection, bacterial DNA extraction methodology, which hypervariable regions of 16S rRNA gene have been amplified, or bioinformatic analysis. In the present work, seminal microbiota of 14 control samples and 42 samples of idiopathic infertile patients were characterized based on full-length sequencing of the 16S rRNA gene using MinION platform from Oxford Nanopore. These same samples had been analyzed previously using Illumina’s MiSeq sequencing platform. Comparison between the results obtained with the two platforms has been used to analyze the impact of sequencing method on the study of the seminal microbiome’s composition. Seminal microbiota observed with MinION were mainly composed of the phyla Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria, with the most abundant genera being Peptoniphilus, Finegoldia, Staphylococcus, Anaerococcus, Campylobacter, Prevotella, Streptococcus, Lactobacillus, Ezakiella and Enterococcus. This composition was similar to that found by the Illumina platform, since these 10 most abundant genera were also among the most abundant genera detected by the Nanopore platform. In both cases, the top 10 genera represented more than 70% of the classified reads. However, relative abundance of each bacterium did not correlate between these two platforms, with intraindividual variations of up to 50 percentage points in some cases. Results suggest that the effect of the sequencing platform on the characterization of seminal microbiota is not very large at the phylum level, with slightly variances in Firmicutes and Actinobacteria, but presents differences at the genus level. These differences could alter the composition and diversity of bacterial profiles or posterior analyses. This indicates the importance of conducting multi-platform studies to better characterize seminal microbioma. This research was funded by the European Regional Development Fund and Instituto de Salud Carlos III (Economy, Industry and Competitiveness Ministry, Madrid, Spain; Project PI14/00119) and Generalitat de Catalunya (2017SGR1796 and 2021SGR00122).
- Published
- 2023
- Full Text
- View/download PDF
50. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts
- Author
-
Girerd, Nicolas, Leclercq, Christophe, Hanon, Olivier, Bayés-Genís, Antoni, Januzzi, James, Damy, Thibaut, Lequeux, Benoit, Meune, Christophe, Sabouret, Pierre, Roubille, François, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpitaux Universitaires Paris Centre, Université Paris Cité (UPCité), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Germans Trias i Pujol University Hospital [Badalona, Barcelona, Spain] (GTPUH), Massachusetts General Hospital [Boston], Harvard Medical School [Boston] (HMS), Baim Institute for Clinical Research Boston MA, CHU Henri Mondor [Créteil], Service de cardiologie [CHU de Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)
- Subjects
Titration ,Cardiovascular diseases ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Practice guidelines treatment algorithm ,Heart failure ,Treatment optimization ,[SDV.IB]Life Sciences [q-bio]/Bioengineering ,General Medicine - Abstract
International audience; Major international practice guidelines recommend the use of a combination of 4 medication classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) but do not specify how these treatments should be introduced and up-titrated. Consequently, many patients with HFrEF do not receive an optimized treatment regimen. This review proposes a pragmatic algorithm for treatment optimization designed to be easily applied in routine practice. The first goal is to ensure that all 4 recommended medication classes are initiated as early as possible to establish effective therapy, even at a low dose. This is considered preferable to starting fewer medications at a maximum dose. The second goal is to ensure that the intervals between the introduction of different medications and between different titration steps are as short as possible to ensure patient safety. Specific proposals are made for older patients (> 75 years) who are frail, and for those with cardiac rhythm disorders. Application of this algorithm should allow an optimal treatment protocol to be achieved within 2-months in most patients, which should the treatment goal in HFrEF.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.